Zeo ScientifiX (ZEOX) 10-K 1 Nov 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Oct. 31, 2017	Nov. 01, 2018	Apr. 28, 2017
Document And Entity Information
Entity Registrant Name	Organicell Regenerative Medicine, Inc.
Entity Central Index Key	1,557,376
Document Type	10-K
Document Period End Date	Oct. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	No
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity Public Float			$ 419,190
Entity Common Stock, Shares Outstanding		432,290,110
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Oct. 31, 2017	Oct. 31, 2016
Current Assets
Cash	$ 39,560	$ 26,223
Accounts receivable, net of allowance for bad debts	107,295	1,125
Accounts receivable - related party	7,665	0
Prepaid expenses	7,003	0
Inventories	119,555	9,944
Total Current Assets	281,078	37,292
Property and equipment, net	53,427	27,606
Security deposits	42,275	5,000
TOTAL ASSETS	376,780	69,898
Current Liabilities
Accounts payable and accrued expenses	592,198	248,847
Accrued liabilities to management	2,184,408	378,274
Notes payable	60,000	100,000
Deferred rent	10,017	0
Deferred revenue	84,000	0
Convertible secured promissory notes - related party, net of debt discount	101,635	0
Convertible secured promissory notes, net of debt discount	59,286	0
Derivative liability of convertible secured promissory notes - related party	419,115	0
Derivative liability of convertible secured promissory notes - third party	244,483	0
Liabilities attributable to discontinued operations	125,851	125,851
Total Current Liabilities	3,880,993	852,972
Commitments and contingencies	0
Deficit
Common stock, $0.001 par value, 750,000,000 shares authorized; 111,464,987 and 104,214,982 shares issued and outstanding, respectively	111,465	104,215
Additional paid-in capital	7,417,321	1,226,322
Accumulated deficit	(11,085,743)	(2,113,611)
Total deficit attributable to Organicell Regenerative Medicine, Inc.	(3,556,957)	(783,074)
Non-controlling interest	52,744	0
Total Deficit	(3,504,213)	(783,074)
TOTAL LIABILITIES AND DEFICIT	376,780	69,898
Series A Preferred Stock [Member]
Deficit
Preferred stock	0	0
Series B Preferred Stock [Member]
Deficit
Preferred stock	$ 0	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Oct. 31, 2017	Oct. 31, 2016
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	111,464,987	104,214,982
Common stock, shares outstanding	111,464,987	104,214,982
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	400	400
Preferred stock, shares issued	400	400
Preferred stock, shares outstanding	400	400
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
Income Statement [Abstract]
Revenues	$ 569,845	$ 184,881
Cost of revenues	160,626	94,402
Gross profit	409,219	90,479
General and administrative expenses	9,050,743	1,133,796
Total Operating Expenses	9,050,743	1,133,796
Loss from operations	(8,641,524)	(1,043,317)
Other income (expense)
Interest expense	(576,016)	(12,729)
Change in fair value of derivative liabilities	95,971	0
Other	9,050	0
Loss from continuing operations	(9,112,519)	(1,056,046)
Loss from discontinued operations	0	(197,155)
Net loss	(9,112,519)	(1,253,201)
Net loss attributable to the non-controlling interest	140,387	0
Net loss attributable to Organicell Regenerative Medicine, Inc.	$ (8,972,132)	$ (1,253,201)
Net loss per common share - basic and diluted:
Continuing operations	$ (0.08)	$ (0.01)
Discontinued operations	0	0
Total	$ (0.08)	$ (0.01)
Weighted average number of common shares outstanding - basic and diluted	108,596,489	100,377,159

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity (Deficit) - USD ($)	Series A Preferred Stock	Series B Preferred Stock	Common Stock [Member]	Additional Paid-In Capital [Member]	Noncontrolling Interest	Accumulated Deficit [Member]	Total
Balance, value at Oct. 31, 2015			$ 99,198	$ 774,060		$ (860,410)	$ 12,848
Balance, shares at Oct. 31, 2015			99,198,114
Proceeds from sale of common stock, value			$ 5,017	452,262		457,279
Proceeds from sale of common stock, shares			5,016,868
Net loss						(1,253,201)	(1,253,201)
Balance, value at Oct. 31, 2016			$ 104,215	1,226,322		(2,113,611)	(783,074)
Balance, shares at Oct. 31, 2016			104,214,982
Proceeds from sale of common stock, value			$ 2,150	102,850		105,000
Proceeds from sale of common stock, shares			2,150,005
Net proceeds from sale of Mint Organics common stock to minority interest				219,450	180,550		400,000
Common stock issued for debt inducement, value			$ 4,000	59,680			63,680
Common stock issued for debt inducement, shares			4,000,000
Stock-based compensation, value			$ 1,100	5,809,019	12,581		5,822,700
Stock-based compensation, shares	400		1,100,000
Net loss					(140,387)	(8,972,132)	(9,112,519)
Balance, value at Oct. 31, 2017			$ 111,465	$ 7,417,321	$ 52,744	$ (11,085,743)	$ (3,504,213)
Balance, shares at Oct. 31, 2017	400		111,464,987

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (9,112,519)	$ (1,253,201)
Net loss from discontinued operations	0	197,155
Net loss from continuing operations	(9,112,519)	(1,056,046)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	19,315	345
Bad debt expense	5,250	500
Stock-based compensation	5,822,700	0
Interest expense related to derivative liabilities in excess of face value of debt	348,249	0
Amortization of debt discount	160,921	0
Change in fair value of derivative liabilities	(95,971)	0
Changes in operating assets and liabilities:
Accounts receivable, net of allowance for bad debts	(111,420)	18,253
Accounts receivable - related party	(7,665)	0
Prepaid expenses	(7,003)	4,163
Inventories	(109,611)	(9,944)
Security deposits	(37,275)	(5,000)
Accounts payable and accrued expenses	343,351	143,523
Accrued liabilities to management	1,806,134	378,274
Deferred rent	10,017	(9,354)
Deferred revenue	84,000	(15,000)
Net cash used in operating activities - continuing operations	(881,527)	(550,286)
Net cash provided by operating activities - discontinued operations	0	2,098
Net cash used in operating activities	(881,527)	(548,188)
CASH FLOWS FROM INVESTING
Purchase of fixed assets	(45,136)	(26,313)
Net cash used in investing activities - continuing operations	(45,136)	(26,313)
Net cash provided by investing activities - discontinued operations	0	6,180
Net cash used in investing activities	(45,136)	(20,133)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of notes payable	235,000	100,000
Payments on notes payables	(100,000)	0
Proceeds from issuance of notes payable - related party	300,000	(300)
Proceeds from sale of common stock and warrants	400,000	457,259
Proceeds from sale of common stock and warrants - minority interest	105,000	0
Net cash provided by financing activities - continuing operations	940,000	556,979
Net cash used in financing activities - discontinued operations	0	0
Net cash provided by financing activities	940,000	556,979
Increase (decrease) in cash	13,337	(11,342)
Cash at beginning of year	26,223	37,565
Cash at end of year	39,560	26,223
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for taxes	0	0
Cash paid for interest	63,093	0
NON-CASH INVESTING AND FINANCING TRANSACTIONS:
Derivative liability of convertible secured promissory note	759,569	0
Common stock issued for debt inducement	$ 63,680	$ 0

1. Organization and Description

1. Organization and Description of Business	12 Months Ended
	Oct. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Organicell Regenerative Medicine, Inc. (formerly Biotech Products Services and Research, Inc.) (“Organicell” or the “Company”) was incorporated on August 9, 2011 in the State of Nevada. On May 29, 2015, Albert Mitrani acquired controlling interest of Organicell through the purchase of 135,000,000 shares of common stock from John Goodhew and subsequently became a director and the sole officer of Organicell. Until October 30, 2015, the Company’s business included the designing, manufacturing, and selling vending tricycles for commercial customers. On October 30, 2015, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with John Goodhew, the Company's director, pursuant to which all of the shares of Bespoke Tricycles, Ltd. (“Bespoke”), a corporation organized under the Laws of England and Wales, were transferred to Mr. Goodhew. As a result of such sale, the Company was no longer in the business of designing, manufacturing, and selling vending tricycles. The purchase price for the shares sold to Mr. Goodhew was $10. On April 23, 2018, the Company and Management and Business Associates, LLC, a Florida limited liability company (“MBA”), executed a Plan and Agreement of Reorganization (“Reorganization Plan”), whereby the Company agreed to issue to MBA an aggregate of 222,425,073 shares of its common stock of the Company, representing 51% of the outstanding shares of common stock of the Company on fully-diluted basis, for $0.001 per share (or an aggregate of $222,425), in consideration for MBA’s founder and Chief Executive Officer, Mr. Manuel Iglesias’ agreement to serve as the Company’s Chief Executive Officer (“CEO”) and a member of the Board of the Company. The Reorganization Plan was effective as of April 13, 2018 (“Effective Date”). The Reorganization Plan also provided for the cancelation and termination of the Company’s previously issued and outstanding Series A Preferred Stock and Series B Preferred Stock. As a result of the above Reorganization Plan, Mr. Iglesias acquired controlling interest of the Company (see Note 5). On May 21, 2018, the Company filed a Certificate of Amendment with the Secretary of State of Nevada to change the Company’s name from Biotech Products Services and Research, Inc. to Organicell Regenerative Medicine, Inc., effective June 20, 2018 (the “Name Change”). As discussed in Note 12, the Name Change has not yet been effectuated in the marketplace by the Financial Industry Regulatory Agency (“FINRA”). Since the June 2015 change in control of our Company and the July 2015 change in the Company’s operations, the Company has been engaged in the health care industry, principally focusing on supplying products and services related to the growing field of regenerative anti-aging medicine. For the year ended October 31, 2017, the Company operated through the following wholly owned subsidiaries: General Surgical of Florida, Inc., a Florida corporation (“General Surgical”) with a business purpose to sell cellular therapy products to doctors and hospitals, Anu Life Sciences, Inc. (“ANU”), a Florida corporation with a business purpose of the development, production and manufacturing of anti-aging and cellular therapy products, Beyond Cells Corp., a Florida corporation (“Beyond Cells”) formed with a business purpose to provide anti-aging and cellular therapy patient marketing and product sales and Mint Organics, Inc. (“Mint Organics”) a Florida corporation and a 55%-owned subsidiary of the Company with a business purpose of operating Medical Marijuana Treatment Centers (“MMTC”) for defined MMTC licensed activities (see Note 15). ANU began operations during November 2016 and commenced sales of its first product offering during February 2017. Mint Organics began operations during February 2017, and also during February 2017, the Company established Mint Organics Florida, Inc., (“Mint Organics Florida”), a Florida corporation and a 96%-owned subsidiary of Mint Organics with a business purpose of operating MMTC’s for defined MMTC licensed activities within Florida. As described in Note 4, on February 5, 2018, ANU sold or transferred to Vera Acquisition LLC, a Utah limited liability company ("Vera") their right, title and interest in certain tangible and other assets associated with its manufacturing operations in exchange for a cash payment of $950,000 and the execution of a long term distribution agreement between Vera and the Company (“Sale”) which provided the Company certain exclusive and non-exclusive rights to distribute future products to be manufactured by Vera, including products that were developed and produced by ANU and additional products that may be developed and produced by Vera in the future. After the completion of the Sale, the Company remains in the business of selling and distributing regenerative biologic therapies based on amnion placental tissue derived products to doctors and hospitals but will now rely on third party supply agreements, rather than from products manufactured internally by ANU, for the supply of these advanced biologically processed cellular and tissue based products. As of October 31, 2017, Mint Organics had not been successful in obtaining the required licenses to operate MMTC’s and had exhausted all of its working capital and therefore was unable to continue efforts towards development of that business. On April 6, 2018, Mr. Taddeo, resigned as the Chief Executive Officer and member of the Board of Directors of Mint Organics and Mint Organics Florida. Mint Organics and Mint Organics Florida are currently not pursuing efforts to obtain licenses to operate MMTC’s and are considering future alternatives. Ethan New York, Inc., a New York corporation (“Ethan NY”), formed with a business purpose of selling clothing and accessories through a retail store, closed operations during June 2016 and the results of Ethan NY are reflected as discontinued operations in the financial statements.

2. Summary of Significant Accou

2. Summary of Significant Accounting Policies	12 Months Ended
	Oct. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Reclassifications Certain prior year amounts have been reclassified to conform with the current financial statement presentation including adjusted footnotes to reflect the presentation of discontinued operations as further discussed in Note 16. Concentrations of Credit Risk The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $250,000 per institution. At October 31, 2017, the Company did not have any cash balances in financial institutions in excess of FDIC insurance coverage. During the fiscal year ended October 31, 2017, the Company had one customer that accounted for approximately $94,130 of revenues (16.2%) and another customer accounted for approximately $93,000 of revenues (16%). At October 31, 2017, the Company had three customers that accounted for approximately $39,000 (37%), $28,000 (26%) and $18,000 (17%) of accounts receivable, respectively. During the fiscal year ended October 31, 2017, the Company purchased raw materials and other supplies used in manufacturing its products from one supplier totaling approximately $169,000 or 70% of the total amount of materials purchased during the period. The Company’s sales and supply agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products and/or the availability of raw materials and/or products from other suppliers. Since February 2017 (and up through the Sale), the Company manufactured and distributed proprietary products that reduced exposure from reliance on third party suppliers of inventory but increased exposure of reliance on raw materials and other supplies used in the manufacturing of its products. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates. Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Accounts Receivable Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company's customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. For the year ended October 31, 2017 and 2016, the Company recorded bad debt expense of $5,250 and $500, respectively. Inventory Inventory is stated at the lower of cost or market using the average cost method. The Company regularly reviews inventory quantities on hand to identify slow-moving merchandise and markdowns necessary to clear slow-moving merchandise. Estimates of markdown requirements may differ from actual results due to changes in quantity, quality and mix of products in inventory, as well as changes in consumer preferences, market and economic conditions. Property and Equipment Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of property and equipment range from 3 to 5 years. Upon sale or retirement, the cost and related accumulated depreciation and amortization are eliminated from their respective accounts, and the resulting gain or loss is included in results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. Revenue Recognition The Company recognizes revenue on arrangements in accordance with FASB ASC Topic. 605 “Revenue Recognition”. In all cases, revenue is recognized only when the price is fixed and determinable, persuasive evidence of an arrangement exists, the service is performed and collectability of the resulting receivable is reasonably assured. Net Income (Loss) Per Common Share Basic income (loss) per common share is calculated by dividing the Company's net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company's net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. At October 31, 2017, the Company had 158,137,484 common shares issuable upon the exercise of warrants that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the year ended October 31, 2017. At October 31, 2016, the Company had 1,737,484 common shares issuable upon the exercise of warrants that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the year ended October 31, 2016. Stock-Based Compensation All stock-based payments to employees, including grants of employee stock options, are recognized in the financial statements based on their fair values. Stock options and warrants issued to consultants and other non-employees as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can be more clearly determined. Income Taxes The Company is required to file a consolidated tax return that includes all of its subsidiaries. Current income taxes are based on the year’s taxable income for federal and state income tax reporting purposes. Deferred income taxes are provided on a liability basis whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax law and rates on the date of enactment. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. For the years ended October 31, 2017 and 2016, the Company has incurred operating losses, and therefore, there were not any income tax expense amounts recorded during that period associated. Since January 1, 2018, the nominal corporate tax rate in the United States of America is a flat 21 percent due to the passage of the "Tax Cuts and Jobs Act" on December 20, 2017 by the US Senate and House of Representatives. Valuation of Derivatives The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date. We analyzed the derivative financial instruments in accordance with ASC 815. The Company utilized Monte Carlo Simulation models that value the derivative liability based on a probability weighted discounted cash flow model. The Company utilized the fair value standard set forth by the Financial Accounting Standards Board, defined as the amount at which the assets (or liability) could be bought (or incurred) or sold (or settled) in a current transaction between willing parties, that is, other than in a forced or liquidation sale. The derivative liabilities result in a reduction of the initial carrying amount (as unamortized discount) of the Convertible Notes. This derivative liability is marked-to-market each quarter with the change in fair value recorded in the income statement. Unamortized discount is amortized to interest expense using the effective interest method over the life of the Convertible Note. Fair Value of Financial Instruments The Company includes fair value information in the notes to financial statements when the fair value of its financial instruments is different from the book value. When the book value approximates fair value, no additional disclosure is made. The Company follows FASB ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measurements. It defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities and convertible debt. The estimated fair value of cash, accounts payable and accrued liabilities approximate their carrying amounts due to the short-term nature of these instruments. The Company follows the provisions of ASC 820 with respect to its financial instruments. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. The Company’s convertible promissory notes (see Note 9) which are required to be measured at fair value on a recurring basis under of ASC 815 as of October 31, 2017 are all measured at fair value using Level 3 inputs. Level 3 inputs are unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities as of October 31, 2017: Level one Level two Level three The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company’s derivative liability is measured at fair value on a recurring basis. The Company classifies the fair value of the derivative liability under level three. Based on ASC Topic 815 and related guidance, the Company concluded the common stock issuable pursuant to conversion of the convertible promissory notes are required to be accounted for as derivatives as of the issue date due to a reset feature on the exercise price. At the date of issuance common stock derivative liabilities were measured at fair value using either quoted market prices of financial instruments with similar characteristics or other valuation techniques. The Company records the fair value of these derivatives on its balance sheet at fair value with changes in the values of these derivatives reflected in the consolidated statements of operations as “change in fair value of derivative liabilities.” These derivative instruments are not designated as hedging instruments under ASC 815-10 and are disclosed on the balance sheet under Derivative Liabilities. Further, and in accordance with ASC 815, the embedded derivatives are revalued using a Monte Carlo Simulation model at issuance and at each balance sheet date and marked to fair value with the corresponding adjustment as a “gain or loss on change in fair values” in the consolidated statement of operations. As of October 31, 2017, the fair value of the derivative liabilities included on the accompanying consolidated balance sheet was $663,598. During the year ended October 31, 2017, the Company recognized a gain on change in the fair value totaling $95,971. The Company classifies the fair value of these securities under level three of the fair value hierarchy of financial instruments. The following table presents liabilities that are measured and recognized at fair value as of October 31, 2017 on a recurring and non-recurring basis: Description Level 1 Level 2 Level 3 Gains (Losses) Derivatives $ – $ – $ 663,598 $ 95,971 Fair Value at October 31, 2017 $ – $ – $ 663,598 $ 95,971 Changes in the unobservable input values would likely cause material changes in the fair value of the Company’s Level 3 financial instruments. Subsequent Events The Company has evaluated subsequent events that occurred after October 31, 2017 through the financial statement issuance date for subsequent event disclosure consideration. New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606).” The new guidance provides new criteria for recognizing revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new guidance requires expanded disclosures to provide greater insight into both revenue that has been recognized and revenue that is expected to be recognized in the future from existing contracts. Quantitative and qualitative information will be provided about the significant judgments and changes in those judgments that management made to determine the revenue that is recorded. This accounting standard update, as amended, will be effective for annual reporting periods beginning after December 15, 2017, and interim reporting periods within annual reporting periods beginning after December 15, 2017. The new revenue standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. Early adoption is permitted, but no earlier than fiscal 2017. The Company has assessed the provisions of the guidance and has determined that there is no impact from the adoption of this guidance on its consolidated financial statements. The Company will adopt the provisions of this guidance beginning in the quarter ended January 31, 2018. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The new standard requires management to assess the company’s ability to continue as a going concern. Disclosures are required if there is substantial doubt as to the company’s continuation as a going concern within one year after the issue date of financial statements. The standard provides guidance for making the assessment, including consideration of management’s plans, which may alleviate doubt regarding the Company’s ability to continue as a going concern. ASU 2014-15 is effective for years ending after December 15, 2016. Early adoption is permitted. The Company has adopted this standard for the year ending October 31, 2017, and management has concluded that there is substantial doubt as to the Company’s continuation as a going concern within one year after the issuance date of the financial statements. In February 2016, a pronouncement was issued by the FASB that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is currently evaluating the impact of the new pronouncement on its financial statements. In April 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation” (topic 718). The FASB issued this update to improve the accounting for employee share-based payments and affect all organizations that issue share based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The updated guidance is effective for annual periods beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption of the update is permitted. The Company adopted this guidance in the first quarter of 2017. The adoption of this update had no material effect on the Company’s financial position or results of operations. The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company's results of operations, financial position or cash flow.

3. Going Concern

3. Going Concern	12 Months Ended
	Oct. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 3 – GOING CONCERN The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has had limited revenues since its inception. The Company incurred a net loss of $9,112,519 for the year ended October 31, 2017. In addition, the Company had an accumulated deficit of $11,085,743 at October 31, 2017. The Company had a negative working capital position of $3,599,915 at October 31, 2017. The Company’s efforts to establish a stabilized source of sufficient revenues to cover operating costs has yet to be achieved and ultimately may prove to be unsuccessful unless additional sources of working capital through operations or debt and/or equity financings are realized. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management anticipates that the Company will remain dependent, for the near future, on additional investment capital to fund ongoing operating expenses. As a result of the Sale, the Company does not have any assets to pledge for the purpose of borrowing additional capital. In addition, the Company relies on non-exclusive supply arrangements to obtain the supply of the products it currently sells and distributes to its customers. The Company’s current market capitalization and common stock liquidity will hinder its ability to raise equity proceeds. The Company anticipates that future sources of funding, if any, will therefore be costly and dilutive. if available at all. In view of the matters described in the preceding paragraphs, recoverability of the recorded asset amounts shown in the accompanying consolidated balance sheet assumes that (1) the Company will be able to establish a stabilized source of revenues, (2) obligations to the Company’s creditors are not accelerated, (3) the Company’s operating expenses remain at current levels and/or the Company is successful in restructuring and/or deferring ongoing obligations, (4) the Company is able to continue to obtain products under current supply arrangements or from other suppliers with similar terms and conditions, and (5) the Company obtains additional working capital to meet its contractual commitments and maintain the current level of Company operations through debt or equity sources. There is no assurance that the Company will be able to complete its revenue growth strategy or otherwise obtain sufficient working capital to cover ongoing cash requirements. Without sufficient cash reserves, the Company’s ability to pursue growth objectives will be adversely impacted. Furthermore, despite significant effort since July 2015, the Company has thus far been unsuccessful in achieving a stabilized source of revenues. If revenues do not increase and stabilize or if additional funds cannot otherwise be raised, the Company might be required to seek other alternatives which could include the sale of assets, closure of operations and/or protection under the U.S. bankruptcy laws. As of October 31, 2017, based on the factors described above, the Company concluded that there was substantial doubt about its ability to continue to operate as a going concern for the 12 months following the issuance of these financial statements.

4. Sale and Transfer of Anu Man

4. Sale and Transfer of Anu Manufacturing Assets	12 Months Ended
	Oct. 31, 2017
Transfers and Servicing [Abstract]
Sale and Transfer of Anu Manufacturing Assets	NOTE 4 – SALE AND TRANSFER OF ANU MANUFACTURING ASSETS Effective February 5, 2018 (“Closing Date”), Vera Acquisition LLC, a Utah limited liability company ("Vera"), Organicell, ANU and General Surgical, executed an Asset Purchase Agreement ("Purchase Agreement") pursuant to which ANU sold to Vera (“Sale”) their right, title and interest in certain tangible and other assets associated with its manufacturing operations, including, prepaid expenses, raw and finished goods inventory, a long term lease for ANU’s laboratory facility in Sunrise, Florida (including associated security deposits), furniture and equipment, and certain intellectual property rights and General Surgical transferred its rights to certain third-party distribution agreements between General Surgical and distributors of products manufactured by ANU (“Sold Assets”) in exchange for a cash payment of $950,000 and the execution of a long term distribution agreement with Organicell (“Organicell Distribution Agreement”) described below. In connection with the Sale, Vera received credit for $100,000 previously paid to ANU for prepaid product supply which was not yet delivered to Vera as of the Closing Date. In connection with the Sale, the Company was required to use cash proceeds from the Sale to satisfy and extinguish all of the Notes outstanding related to the SPA as of the date of the Sale, totaling approximately $762,477 (comprised of $527,778 of face value of the Notes outstanding, $8,589 of accrued and unpaid interest from January 1, 2018 through the date of the Sale, $211,111 of prepayment penalties and $15,000 for reimbursement of legal fees), which were secured by a first priority lien on all of the Company’s assets, and to be used to pay all of ANU’s remaining trade accounts payable outstanding as of the Closing Date. In addition, the Purchase Agreement required ANU to fund the placental donor tissue costs that were required by Vera to process additional product subsequent to the Closing to replace the shortfall of the actual inventory product amounts as of the Closing Date and the specified inventory quantities provided for in the Purchase Agreement. The Purchase Agreement also required ANU to escrow $47,500 (5%) of the cash purchase price and for General Surgical to escrow, subsequent to the Closing Date, up to $47,500 from collections of accounts receivable that were existing as of the Closing Date for a period of 90 days subsequent to the Closing Date to cover pre-closing related liabilities of ANU that were not identified as of the Closing Date, if any, and other obligations of ANU associated with the Purchase Agreement. Vera is obligated to repay to the Company the net portion of the escrowed amounts held by Vera that are remaining upon the expiration of the 90 day escrow period and upon such time that the Company delivers a certificate of compliance from the State of Florida that there are no taxes owing to the State of Florida by ANU related to activities prior to Sale or the transfer of the Sold Assets. The Purchase Agreement also required the Company to indemnify Vera for future claims made against Vera related to activities of ANU occurring prior to the Closing Date. In connection with the Sale, the Company and the Company’s executives as of the date of the Sale, executed non-competition covenant agreements whereby each party, including their affiliates, agreed under certain circumstances, not to engage directly or by assisting others in conducting activities competitive with Vera (defined as distributing, manufacturing, designing or engineering placental tissue-based products), except in a capacity of performing the activities related to the Organicell Distribution Agreement. Effective upon the closing of the Sale, the Chief Operating Officer (“COO”) and Chief Technical Officer (“CTO”) each entered into a separation and general release agreement with the Company, which provided for the immediate resignation of the COO and CTO of all their respective executive and board of director positions held with Organicell and/or any of Organicell’s subsidiaries, and settlement of all obligations of each party to the other pursuant to the respective employment agreements, including the release of all rights the Company may have held in any intellectual property of the COO and CTO and any non-compete restrictions on the COO and CTO. In connection with such releases, each of the COO and CTO agreed to forfeit all warrants previously granted and outstanding (a total of 77,150,000 warrants to purchase shares of common stock of the Company), forfeit any and all accrued and unpaid amounts owing under the employment agreements for past due wages, benefits, severance obligations, unreimbursed expenses and any other obligations owing to one another as of the Closing Date in exchange for a grant of 7,500,000 newly issued shares of restricted common stock of the Company to each of the COO and CTO, with a fair value of $82,500, based on the closing price of the common stock of the Company on the date of the Sale. In connection with the Sale, ANU and General Surgical retained all cash on-hand as of the Closing Date and General Surgical retained all accounts receivable existing at the Closing Date, trademarks and inventory associated with the distribution of its “Organicell” product, and certain agreements between General Surgical and distributors of the ANU products that General Surgical intends to continue to supply after the Closing Date pursuant to the Organicell Distribution Agreement. After the completion of the Sale, the Company remains in the business of selling and distributing regenerative biologic therapies based on amnion placental tissue derived products to doctors and hospitals but will now rely on the Organicell Distribution Agreement, rather than from products manufactured internally by ANU, for the supply of these advanced biologically processed cellular and tissue based products, including those same products previously produced by ANU and newly developed products that may become available from Vera or other suppliers in the future. Organicell Distribution Agreement In connection with the Sale, the Company and Vera entered into a long-term distribution agreement (“Organicell Distribution Agreement”) which provided Organicell, or its designees, certain exclusive and non-exclusive rights to distribute future products to be manufactured by Vera, including products that were developed and produced by ANU prior to the Closing Date and additional products that may be developed and produced by Vera in the future. The initial term of the Organicell Distribution Agreement is for three years and is automatically renewed for additional one-year periods, subject to Organicell meeting minimum volume purchase requirements. The Organicell Distribution Agreement provides pricing for those products which were produced and available from ANU at the time of the Sale, and discounts based on Organicell achieving minimum monthly purchase volumes. Under the terms of the Organicell Distribution Agreement, the Company was obligated to purchase the Vera products identified at the time of the Sale, provided they are available to be purchased from Vera and/or new products developed after the time of the Sale, provided that the Company and Vera can mutually agree on the terms for the sale of the new product offerings. During August 2018, Vera notified the Company that it was no longer in the business originally acquired in connection with the Sale and that it was no longer able to supply products to the Company under the Organicell Distribution Agreement. As a result, the Company is currently relying on short-term supply agreements with other third party manufacturers to provide it with the products it currently distributes.

5. Reorganization Plan

5. Reorganization Plan	12 Months Ended
	Oct. 31, 2017
Reorganizations [Abstract]
Reorganization Plan	NOTE 5 – REORGANIZATION PLAN On April 23, 2018, the Company and MBA, executed a Plan and Agreement of Reorganization (“Reorganization Plan”) whereby the Company agreed to issue to MBA an aggregate of 222,425,073 shares of its common stock, representing 51% of the outstanding shares of common stock of the Company on fully-diluted basis, for $0.001 per share (or an aggregate of $222,425), in consideration for MBA’s founder and Chief Executive Officer, Mr. Manuel Iglesias’ agreement to serve as the Company’s Chief Executive Officer and a member of the Board of the Company. The Reorganization Plan was effective as of April 13, 2018. Under the terms of the Reorganization Plan, as of the Effective Date: 1. Mr. Iglesias replaced Albert Mitrani as Chief Executive Officer of the Company. 2. Mr. Iglesias and Richard Fox were appointed as members to the Board of Directors of the Company. 3. Ian Bothwell and Maria Mitrani resigned from the Board of Directors of the Company. 4. Albert Mitrani, Ian Bothwell and Maria Mitrani each agreed to terminate their respective employment agreements in favor of new employment agreements. In connection with the new employment agreements, Mr. Mitrani agreed to serve as the Company’s President, Ian Bothwell agreed to remain Chief Financial Officer and Maria Mitrani agreed to remain Chief Science Officer of the Company. 5. Albert Mitrani, Ian Bothwell and Maria Mitrani each agreed to the cancellation of their 100 shares of the Company’s Series A Preferred Stock. In addition, the Company agreed that it would cancel the Certificates of Designation for the Company’s Series A Preferred Stock and Series B Preferred Stock. 6. The Company agreed to terminate Sections 4.08(c) and 4.08(d) of the Company’s Second Amended and Restated By-Laws which had required supermajority approval of the Board for certain corporate actions. 7. Ian Bothwell and Maria Mitrani exercised, on a cashless basis, all of their warrants for 48,624,561 and 21,757,895, respectively, shares of common stock of the Company based on the exercise price of $0.001 and the closing price of the Company’s common stock on the Effective Date. 8. Ian Bothwell and Maria Mitrani were granted an additional 4,675,439 and 2,092,105, respectively, shares of common stock of the Company. 9. Albert Mitrani, Ian Bothwell and Maria Mitrani each agreed to release the Company for all amounts owed to them for unpaid salaries through the Effective Date and advances and/or expenses incurred prior to December 31, 2017. As a result of the above transactions, MBA has a controlling interest in the voting and equity interests of the Company.

6. Inventories

6. Inventories	12 Months Ended
	Oct. 31, 2017
Inventory Disclosure [Abstract]
Inventories	NOTE 6 – INVENTORIES Inventories totaled $119,555 and $9,944 at October 31, 2017 and October 31, 2016, respectively. October 31, 2017 October 31, 2016 Raw materials and supplies $ 17,637 $ 9,944 Finished goods 101,918 – Total inventories $ 119,555 $ 9,944 As described in Note 4, in connection with the Sale, ANU sold or transferred to Vera its right, title and interest in the manufacturing related inventories that were on hand as of the date of the Sale.

7. Property and Equipment

7. Property and Equipment	12 Months Ended
	Oct. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 7 - PROPERTY AND EQUIPMENT October 31, 2017 October 31, 2016 Computer equipment $ 4,084 $ 1,724 Manufacturing equipment 69,089 26,313 73,173 28,037 Less: accumulated depreciation and amortization (19,746 ) (431 ) Total property and equipment, net $ 53,427 $ 27,606 Depreciation expense of property, plant and equipment from operations totaled $19,315 and $345 for the years ended October 31, 2017 and 2016, respectively. As described in Note 4, in connection with the Sale, ANU sold or transferred to Vera its right, title and interest in the manufacturing related equipment existing as of the date of the Sale.

8. Related Party Transactions

8. Related Party Transactions	12 Months Ended
	Oct. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 8 – RELATED PARTY TRANSACTIONS During the fiscal year ended October 31, 2016, the Company recorded salary expense to its CEO in the amount of $241,845, of which $91,845 was paid through October 31, 2016. The Company also recorded salary and consulting fees to the CEO’s wife in the amount of $138,729, of which $33,896 was paid through October 31, 2016. Expenses of approximately $44,000 were reimbursed in relation to the consulting services provided. In addition, the Company also made payments on behalf of the CEO and the CEO’s wife for health benefit costs and automobile related allowances totaling approximately $46,868 for the fiscal year ended October 31, 2016. As described below, as of October 31, 2016, the Company recorded an aggregate of $150,000 and $104,833 of accrued salary related expenses owed to the CEO and the CEO’s wife, respectively, for all advances, loans, consulting fees and/or salary related compensation owed to each of the CEO and/or CEO’s wife through October 31, 2016. Prior to November 4, 2016, the CEO and the CEO’s wife did not have employment agreements or consulting agreements with the Company and had agreed to defer any future salary or consulting payments based on availability of cash resources of the Company. As more fully described in Note 14, effective November 4, 2016, the Company entered into executive employment agreements with Albert Mitrani, the CEO; the CEO’s wife Maria Mitrani, the Chief Science Officer (“CSO”); Bruce Werber, the COO; and Ian Bothwell, the Chief Financial Officer (“CFO”). On March 8, 2017, the Company entered into an executive employment agreement with Terrell Suddarth, the CTO, and amended the CSO’s, the COO’s and CFO’s executive employment agreements. During April 2018, the Company amended the CSO’s and the CFO’s executive employment agreements. (collectively the CEO, CSO, COO, CFO’s and CTO’s executive employment agreements, as amended, are referred to as the “Executive Agreements”). In connection with the executive employment agreements with the CEO and the CSO, the Company agreed to pay a total of $150,000 and $104,833, respectively, representing the total amount of all advances, loans, consulting fees and/or salary related compensation owing to each of the CEO and the CSO up through November 4, 2016. The payment of the above amounts was to be paid in the future based on the available cash of the Company. Effective February 5, 2018, the COO’s and CTO’s executive employment agreements were terminated. Effective April 13, 2018, the CEO’s, CFO’s and CSO’s executive employment agreements were terminated and replaced with new executive employment agreements (“New Executive Employment Agreements”). See Note 14 for a more detailed description of the Executive Agreements and New Executive Employment Agreements. In connection with the Reorganization Plan, the CFO and CSO each agreed to exercise on a cashless basis all of their warrants to purchase 53,300,000 and 23,850,000 shares of common stock of the Company, respectively. Based on the closing price of the Company’s common stock on the Effective Date of $0.016 per share and the warrant exercise price of $0.001 per share, the CFO and CSO were required to use 4,675,439 and 2,092,105 shares of common stock received from the exercise of the warrants, respectively, to pay for the exercise price for exercising all of the warrants. Effective April 13, 2018, the CFO and CSO were each granted 4,675,439 and 2,092,105 shares of common stock of the Company, respectively. The newly granted shares vest immediately and were valued at $74,807 and $33,474, respectively, based on the closing trading price of the common stock on the effective date of the grant. Effective August 1, 2016, the Company’s corporate administrative offices were moved to office space in Miami Beach, Florida. The office space is leased from MariLuna, LLC, a Florida limited liability company which is owned by the CSO. The term of the lease is 24 months and the monthly rent is $2,500. The Company paid a security deposit of $5,000. During April 2018, the lease was renewed for an additional 24 months at a monthly rent of $2,800. In connection with the 2016 and 2018 executive employment agreement between the Company and the CFO, the Company agreed to reimburse Rover Advanced Technologies, LLC, a company owned and controlled by the CFO for office rent and other direct expenses (phone, internet, copier and direct administrative fees, etc.) up to a maximum of $2,500 per month. As of March 29, 2017, the CFO and COO, were owed $150,000 and $150,000, respectively, by the Company for advances and unreimbursed expenses in connection with the Company’s operations through March 29, 2017. On March 29, 2017, in connection with the SPA (see Note 9), the advances and unreimbursed expenses owed to the CFO and COO totaling $300,000 were converted and incorporated in the initial tranche funding amounts as provided for in the SPA. As a result of the conversion, the advances and unreimbursed expenses became secured obligations of the Company, and were payable, convertible into common shares of the Company in accordance with the terms of the SPA. The CFO and the COO were also each granted 1,000,000 common shares of the Company valued at $31,840 based on the closing price of the common stock of the Company on the date the stock was issued. On February 5, 2018, in connection with the Sale (see Note 4), all amounts owed to the CFO and COO in connection with the SPA were repaid. On November 1, 2016, the Company issued 100 shares of Series A Non-Convertible Preferred Stock, par value $0.001 per share (“Series A Preferred Stock”) to the CEO. On March 8, 2017, the Company issued 100 shares of the Series A Preferred Stock, to each the COO, CSO and CFO. The Series A Preferred Stock shall vote together with the shares of common stock and other voting securities of the Company as a single class and such shares shall represent 80% of all votes entitled to be voted at any annual or special meeting of stockholders of the Company or action by written consent of stockholders. The Company determined that the value attributable to the Series A Preferred Stock issued were nominal. On February 5, 2018, in connection with the COO’s resignation and termination, the COO agreed to forfeit and the cancellation of the 100 shares of the Series A Preferred Stock previously issued. Effective April 13, 2018, in connection with the Reorganization Plan, the CEO, CFO and CSO each agreed to the forfeit and cancellation of their 100 shares of the Series A Preferred Stock. On March 8, 2017, Mint Organics, Inc. issued warrants to the CEO, CSO and CFO to each purchase 79 shares of the Class A Common Stock, of Mint Organics, Inc., vesting on the date Mint Organics, Inc., through one of its subsidiaries, obtains a license from any state to dispense cannabis until the fifth anniversary thereof at an exercise price of $0.001 per share. During February 2017, the Company sold 250,000 shares of its common stock to the COO’s daughter at $0.04 per share for an aggregate purchase price of $10,000 based on the closing price of the common stock of the Company on the date the stock was issued. As described in Note 15, on February 14, 2017, Mr. Peter Taddeo and Mr. Wayne Rohrbaugh each invested $150,000 in the Company in connection with the Company’s endeavor, through Mint Organics, Inc., to obtain a license to dispense medical cannabis in Florida. In consideration for their investment, on February 28, 2017, Mr. Taddeo and Mr. Rohrbaugh were each issued 150 shares of Mint Series A Preferred Stock of Mint Organics, Inc. and a warrant from the Company to purchase up to 150,000 shares of common stock of the Company for $0.15 per share, exercisable from the date of issuance of the warrant until the third anniversary date of the date of issuance. Mr. Taddeo was also appointed as the Chief Executive Officer and as a director of Mint Organics, Inc. and Mint Organics Florida, Inc. (Mint Organics Inc. and Mint Organics Florida Inc. are collectively referred to as the “Mint Organics Entities”). Mr. Rohrbaugh was also appointed as the Chief Operating Officer and as a director of the Mint Organics Entities. The Mint Series A Preferred Stock is convertible into Class B Common Stock of Mint Organics, Inc. or into common stock of the Company. On May 17, 2017, Mint Organics entered into an executive employment agreement with Peter Taddeo, the CEO of Mint Organics (the “Taddeo Agreement”). In connection with the Taddeo Agreement, the Company granted Taddeo 1,000,000 shares of unregistered restricted common stock valued at $0.012 per share, the closing price of the common stock of the Company on the date of grant. The shares vested on December 31, 2017. See Note 15 for a more detailed description of the Taddeo Agreement. On April 6, 2018, Peter Taddeo resigned as a member of the Board of Directors of the Company and as the Chief Executive Officer and member of the board of directors of the Mint Organics Entities. In connection with Mr. Taddeo’s resignation, Mr. Taddeo entered into a Separation and General Release Agreement (“Taddeo Separation Agreement”) whereby Mr. Taddeo agreed to release the Mint Organics Entities from all obligations in connection with the Taddeo Agreement and all other agreements and/or financial obligations between the parties related to the Taddeo’s employment or services performed with any of Mint Organics Entities. In consideration for Taddeo entering into the Taddeo Separation Agreement, the Mint Organics Entities paid Taddeo $5,000 and Mr. Bothwell paid $3,000 to Taddeo for the purchase of the 1,000,000 shares of common stock of the Company that were granted to Taddeo in connection with the Taddeo Agreement. Contemporaneously with the execution of the Taddeo Separation Agreement, the Company and Mr. Taddeo entered into a Share Purchase and General Release Agreement whereby the Company agreed to purchase from Mr. Taddeo his 150 shares of Mint Series A Preferred Stock for an aggregate purchase price of $40,000 (see Note 15). As described in Note 5, on April 23, 2018, the Company and MBA, executed a Plan and Agreement of Reorganization. As a result of the Reorganization Plan, Mr. Iglesias acquired controlling interest of the Company. Certain of the Company’s customers are related and/or affiliated with employees and/or consultants of the Company. For the year ended October 31, 2017, the total amount of sales to customers related to employees and/or consultants of the Company totaled $67,550.

9. Notes Payable

9. Notes Payable	12 Months Ended
	Oct. 31, 2017
Debt Disclosure [Abstract]
Notes Payable	NOTE 9 - NOTES PAYABLE On November 12, 2015, the Company entered into an unsecured loan agreement (“$15,000 Note Payable”) with an unaffiliated lender pursuant to which the Company received proceeds of $15,000. The $15,000 Note Payable bears interest at 8% per annum compounded annually and was due one year after the date of issuance. On April 3, 2017, in connection with the SPA, the $15,000 Note Payable plus accrued interest was fully paid (see below). On December 24, 2015, the Company entered into an unsecured loan agreement (“$50,000 Note Payable”) with an unaffiliated lender pursuant to which the Company received proceeds of $50,000. The $50,000 Note Payable bears interest at 8% per annum compounded annually and was due one year after the date of issuance. On April 3, 2017, in connection with the SPA, the $50,000 Note Payable plus accrued interest was fully paid (see below). On April 27, 2016, the Company entered into an unsecured loan agreement (“$35,000 Note Payable”) with a consultant of the Company pursuant to which the Company received proceeds of $35,000. The payoff amount of the $35,000 Note Payable was $42,000 and was due on May 31, 2016 (an annualized interest rate of approximately 221%). On April 3, 2017, in connection with the SPA, the $35,000 Note Payable plus accrued interest was fully paid (see below). SPA - Convertible Promissory Note On March 29, 2017, the Company entered into a Securities Purchase Agreement, dated March 29, 2017 (“SPA”), with an unaffiliated “accredited investor” (“Agent”), Dr. Bruce Werber, the Company’s Chief Operating Officer and a member of the Board of Directors of the Company (“Werber”), and Ian T. Bothwell, the Company’s Chief Financial Officer and member of the Board of Directors (“Bothwell”) (each, including its successors and assigns, a “Purchaser“ and collectively, the “Purchasers”). The transactions contemplated by the SPA were consummated on April 3, 2017. Purchase and Sale Pursuant to the SPA, the Purchasers shall be entitled to purchase a 10% Original Issue Discount Convertible Secured Promissory Note and Guarantee in the principal amount of up to $1,666,667, corresponding to a subscription amount of up to $1,500,000 (“Note”). The purchase of the Note is to occur in several tranches (each a “Tranche”) pursuant to the terms and conditions of the SPA. In connection with the terms of the SPA, the Purchasers agreed to subscribe to the initial Tranche through the second Tranche for an amount in the aggregate of up to $600,000 (subject to adjustment as described in the SPA) corresponding to an aggregate of up to $666,667 in principal amount of the Note. The initial Tranche of $475,000 (which correlates to a principal amount of $527,778 of the Note) was consummated on the closing of the SPA, of which an aggregate of $300,000 (which correlates to a principal amount of $333,333 of the Note) was funded through the rollover of unreimbursed advances and expenses made to the Company by Werber and Bothwell prior to the closing date of the SPA and the remaining $175,000 was funded at closing by the Agent. The second Tranche for $125,000 ($138,889 in principal amount of the Note) was required to be funded to the Company by the Agent on July 15, 2017, upon the Company’s request, subject to certain conditions contained in the SPA. The Company did not request the Agent to fund the second Tranche. Subject to the acceleration and/or prepayment provisions as provided for in the SPA, all unpaid principal, fees and accrued and unpaid interest of the Note was due and payable in full on March 31, 2018. The unpaid principal amount of the Note shall accrue interest at 10% per annum, provided that upon the occurrence and during the continuance of an event of default as defined in the SPA, the outstanding principal amount of this Note and any accrued and unpaid interest and all other overdue amounts shall each bear interest until paid at the rate of 18% per annum. Additionally, in the event that the publicly traded price of the common stock falls below $0.0125 for 3 consecutive trading days, then the Note shall accrue interest at the default interest rate. During the period from April 27, 2017 to May 1, 2017, the closing price of the common stock fell below $0.0125, and accordingly beginning May 2, 2017, the default interest rate of 18% was in effect. Accrued interest shall be payable commencing on June 30, 2017, and continuing on the last business day of each subsequent calendar quarter. Interest expense for the year ended October 31, 2017 was $56,594. The Company made all of the required interest payments during the year ended October 31, 2017, totaling $47,108. In the event of a conversion of this Note prior to the maturity date, all accrued and unpaid interest was to be added to the principal amount being converted as of the date of conversion to determine the amount of securities into which the Note shall be converted. In connection with the terms of the SPA, as of September 19, 2017, the Company had reserved 82,008,230 shares of the authorized common stock of the Company in favor of the Agent and is obligated to ensure that there is an adequate number of reserved shares in favor of the Agent in the future in accordance with the provisions contained in the SPA. In connection with the terms of the SPA, the Company issued the Agent, Werber and Bothwell a total of 2,000,000, 1,000,000 and 1,000,000 common shares of the Company (“Commitment Shares”), respectively, valued in the aggregate at $63,580, based on the closing price of the common stock of the Company on the date the stock was issued. The Note At any time after the six (6) month anniversary of the closing date and until this Note is no longer outstanding, any outstanding principal portion of this Note shall be convertible, in whole or in part, into shares of common stock of the Company at the option of each Purchaser (subject to the conversion limitations set forth in the SPA). According to the SPA, the Purchasers may fund the Company in different Subscription Amounts at each closing after the second Tranche and are not required to participate in each such subsequent Tranche. In the event that any Purchaser does not participate in any Tranche after the second Tranche, the remaining Purchasers shall have the right to participate in such Tranche in an amount up to 100% of the entire Tranche. In the event that such participating Purchasers do not collectively fund 100% of the desired Tranche amount, then the Company shall be permitted to request from any Person (as defined in the SPA) the remaining amount, so long as such Person(s) agree to execute the SPA (and further, the Company and the Purchasers agree to amend the Agreement and the Note as necessary). The Company is not obligated to consummate any additional Tranche fundings subsequent to the second Tranche. The SPA contains customary representations, warranties and covenants for similar transactions by the Company and Purchasers, including restrictions on incurrence of future indebtedness and/or issuance of equity. In addition, included in the covenants was a covenant made by the Company to be up to date with all of its filings with the Securities and Exchange Commission by July 15, 2017, including without limitation, all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Exchange Act of 1934, as amended. The Company met the required deadline for such filings. The Company used the proceeds received at closing from the initial tranche for general working capital purposes and the repayment of all outstanding obligations owed in connection with the $15,000 Note Payable, the $50,000 Note Payable, and the $35,000 Note Payable. In connection with the SPA, the Company recorded an original issue discount of $116,458 consisting of the discount in the aggregate cash received at closing and the intrinsic value of the Commitment Shares. In addition, the Company performed an independent valuation (using Monte Carlo Simulation Models) of the underlying value attributable to the embedded derivatives liabilities associated with the Notes at the issuance date (the Notes contain full ratchet reset provisions and variable market based conversion derivative features) and determined that the fair value of the derivative liabilities associated with the Note was $759,569. As a result, the Company recorded the amount of the derivative liabilities at the time of closing as a reduction of the remaining initial carrying amount of the Notes of $411,320 (as unamortized discount) and the excess amount of $348,249 after reducing the initial carrying amount of the Note to $0, as interest expense. The derivative liability will be marked-to-market each quarter with the change in fair value recorded in the income statement. During the year ended October 31, 2017, the Company recorded a gain of $95,971 associated with change in fair value at October 31, 2017 from the fair value previously determined for the period from the closing date though October 31, 2017. Unamortized discount is amortized to interest expense using the effective interest method over the life of the Note ($366,857 for the year ended October 31, 2017). Security Agreement As an inducement for the Agent to fund the Company, on March 29, 2017, the Company and its subsidiaries: ANU; General Surgical Beyond Cells; BD Source and Distribution, Corp., a Florida corporation; Ethan New York; Mint Organics, Inc., and Mint Organics Florida, (each a “Subsidiary” or “Guarantor” and together, the “Guarantors”) entered into a Security Agreement, dated March 29, 2017 (the “ Security Agreement “), with the Agent, whereby Organicell and each Subsidiary granted the Agent a perfected, first priority security interest in and to all of their respective tangible and intangible assets, whether presently owned or existing or hereafter acquired or coming into existence and all proceeds therefrom, and including the capital stock of each Guarantor. In addition, upon the full satisfaction of the obligations owing to the Agent, all other Purchasers (excluding the Agent) shall assume the security rights of the Agent described above until all of their respective amounts owed by the Company have been fully repaid. Intellectual Property Security Agreement On March 29, 2017, Organicell and the Guarantors entered into an Intellectual Property Security Agreement (the “IP Security Agreement”) with the Agent, whereby Organicell and each Guarantor granted the Agent a perfected, first priority security interest in and to all of their respective intellectual property. Subsidiary Guarantee On March 29, 2017, the Subsidiaries entered into a Subsidiary Guarantee (the “Subsidiary Guarantee”) in favor of the Agent. Pursuant to the Subsidiary Guarantee, the Subsidiaries, jointly and severally, unconditionally and irrevocably, guaranteed the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the obligations of the Company to the Agent and its respective successors, endorsees, transferees and assigns under the Subsidiary Guarantee, the Note and Intellectual Property Security Agreement and any documents executed and delivered in connection therewith. Repayment Of SPA – Convertible Promissory Note In connection with the Sale, (see Note 4). the Company was required to use cash proceeds from the Sale to satisfy and extinguish all of the Notes outstanding related to the SPA as of the date of the Sale, totaling $762,478, comprised of $527,778 of face value of the Notes outstanding, $8,589 of accrued and unpaid interest from January 1, 2018 through the date of the Sale, $211,111 of prepayment penalties and $15,000 for reimbursement of Agent legal fees. In connection with the repayment of the Notes, the Agent has released all of the shares of common stock of the Company previously reserved in favor of the Agent and the Agent has released all of the collateral previously pledged in connection with the SPA. As a result of the repayment of the Notes, any remaining balance of the derivative liabilities outstanding as of the date of the Sale will be written off. Private Placement Of Convertible 6% Debentures On June 20, 2018, the Company issued a total of $150,000 of convertible 6% debentures (“150,000 Debentures”) to an accredited investor. The principal amount of the $150,000 Debentures, plus accrued and unpaid interest through June 30, 2019 are payable on the 10 th th On August 10, 2018, the Company issued a total of $100,000 of convertible 6% debentures (“100,000 Debentures”) to two accredited investors. The principal amount of the $100,000 Debentures, plus accrued and unpaid interest through July 31, 2019 are payable on the 10 th th Under the terms of the $150,000 Debentures and the $100,000 Debentures, the Company is permitted to issue additional convertible 6% debentures up to a maximum aggregate principal amount of $1,000,000 of convertible 6% debentures (“Convertible 6% Debentures”), all of like tenor except as to the issuance date which shall be determined based on the date that additional Convertible 6% Debentures are issued, if any. The Company used the $150,000 and $100,000 of proceeds received for general working capital purposes. The Convertible 6% Debentures may be prepaid at any time by the Company in whole or in part without penalty upon 30 days written notice but not to exceed 60 days (“Repayment Notice”) at a price equal to the principal amount of Convertible 6% Debentures’ elected to be repaid by the Company, plus all unpaid and accrued interest up through the date of prepayment provided in the Repayment Notice (“Prepayment Date”). The $150,000 Debentures (the principal and all accrued but unpaid interest thereon) is subject to conversion at the option of the holder at any time, from time to time, commencing 30 trading days after effectiveness of the Company's pending reverse stock split and continuing up to 5 days prior to maturity and (b) at any time during the period following receipt of a Repayment Notice and up to 5 days prior to the date of Prepayment Date, into shares of the common stock of the Company at a Conversion Price equal to eighty percent (80%) of the Volume Weighted Average Price ("VWAP") of the common stock of the Company. For purposes of this conversion provision, the VWAP of the common stock of the Company as of a particular conversion exercise date shall be determined as the volume weighted average price of the common stock as then reported in the OTC Markets over the 10 trading day period ending on the trading day immediately prior to the conversion exercise date. The $100,000 Debentures (the principal and all accrued but unpaid interest thereon) is subject to conversion at the option of the holder at any time, from time to time, commencing 30 trading days after effectiveness of the Company's pending reverse stock split and continuing up to 5 days prior to maturity and (b) at any time during the period following receipt of a Repayment Notice and up to 5 days prior to the date of Prepayment Date, into shares of the common stock of the Company at a conversion price equal to $0.45 per share. In connection with the Convertible 6% Debentures, the Company will record the underlying value attributable to the fair value of the embedded derivatives liabilities associated with the $150,000 Debentures and $100,000 Debentures at the time that the contingencies surrounding the ability to convert the $150,000 Debentures and/or the $100,000 Debentures are determinable (“Trigger Date”) based on an independent valuation using a Monte Carlo Model. The Company will record the amount of the derivative liabilities as of the Trigger Date as a reduction of the remaining initial carrying amount of the Convertible 6% Debentures and the excess amount after reducing the initial carrying amount of the $150,000 Debentures and $100,000 Debentures to $0, if any, as a charge to the income statement. The derivative liability will be marked-to-market each quarter with the change in fair value recorded in the income statement. Unamortized discount is amortized to interest expense using the effective interest method over the life of the $150,000 Debentures and $100,000 Debentures. Mint Organics Inc. On June 22, 2017, Mint Organics entered into an unsecured loan agreement with a third party with a principal balance of $60,000, an annual interest rate of 10%, and all accrued and unpaid interest and outstanding principal are due on the one-year anniversary of the note. Interest expense for the year ended October 31, 2017 was $2,170. The loan was not repaid on the maturity date as required and remains outstanding.

10. Derivative Liabilities

10. Derivative Liabilities	12 Months Ended
	Oct. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	NOTE 10 – DERIVATIVE LIABILITIES In connection with the sale of debt or equity instruments, the Company may sell options or warrants to purchase our common stock. In certain circumstances, these options or warrants may be classified as derivative liabilities, rather than as equity. Additionally, the debt or equity instruments may contain embedded derivative instruments, such as embedded derivative features which in certain circumstances may be required to be bifurcated from the associated host instrument and accounted for separately as a derivative instrument liability. The Company's derivative instrument liabilities are re-valued at the end of each reporting period, with changes in the fair value of the derivative liability recorded as charges or credits to income in the period in which the changes occur. For options, warrants and bifurcated embedded derivative features that are accounted for as derivative instrument liabilities, the Company estimates fair value using either quoted market prices of financial instruments with similar characteristics or other valuation techniques. The valuation techniques require assumptions related to the remaining term of the instruments and risk-free rates of return, our current common stock price and expected dividend yield, and the expected volatility of our common stock price over the life of the instrument. The following table summarizes the derivative liability activity for the year ending October 31, 2017: Description Derivative Liabilities Fair value at October 31, 2016 $ – Change due to issuances 759,569 Change in fair value (95,971 ) Fair value at October 31, 2017 $ 663,598 For the year ended October 31, 2017, net change in fair value of derivative liabilities was $95,971. The Company classifies the fair value of these securities under level three of the fair value hierarchy of financial instruments. The fair value of the derivative liability was calculated using a Monte Carlo Simulation model that values the liability of the Convertible Notes based on a risk neutral valuation where the price of the option is its discounted expected value. The technique applied generates a large number of possible (but random) price paths for the underlying (or underlyings) via simulation, and then calculate the associated conversion value (i.e. "payoff") of the note (limited buy a percentage of trading volume) for each path. These payoffs are then averaged and discounted to the date of valuation resulting in the fair value of the option. The valuation of the embedded derivatives within the convertible note was completed with the following assumptions: Assumptions April 3, 2017 October 31, 2017 Dividend yield 0.00% 0.00% Risk-free rate for term 1.14% 1.49% Volatility 255.2% 255.3% Remaining Term (years) 1.0 1.50 Stock Price $ 0.0159 $ 0.0084

11. Income Taxes

11. Income Taxes	12 Months Ended
	Oct. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 11 — INCOME TAXES The Company is required to file a consolidated tax return that includes all of its subsidiaries. For the fiscal years ended October 31, 2017 and 2016, the Company has incurred operating losses, and therefore, there were not any tax expense amounts recorded during those years. The cumulative net operating loss carry-forward is approximately $4,749,000 and will expire beginning in 2031 and may be subject to further limitations resulting from the change in control during April 2018. A reconciliation of the U.S. federal statutory tax amount to the Company’s effective tax amount is as follows: Year Ended October 31, 2017 Year Ended October 31, 2016 Income tax benefit at statutory rate (34%) $ (3,098,256 ) $ (426,088 ) Stock-based compensation 1,975,704 – Derivative liabilities & other 135,334 – Change in valuation allowance 987,218 426,088 Total $ – $ – The tax effects of temporary differences and carry-forwards that give rise to deferred tax assets and liabilities for the Company were as follows: October 31, October 31, 2017 2016 Deferred tax asset attributable to: Net operating loss carry-forward $ 1,614,725 $ 627,507 Less valuation allowance (1,614,725 ) (627,507 ) Total $ – $ – The ultimate realization of deferred tax assets depends on various factors including the generation of taxable income in future periods. The Company has concluded that the future sources of taxable income do not assure the realization of 100% of the deferred tax assets. Therefore, the Company has recorded a valuation allowance in the amount of 100% of the deferred tax assets due to the uncertainty of realizing the deferred tax assets. IRS Penalties The Company’s income tax returns for the periods since inception through the tax year ended October 31, 2015 were not filed with the Internal Revenue Service (“IRS”) until August 2017 (“Delinquent Filed Returns”). The Company’s income tax returns for the tax year ended October 31, 2016 were filed with the IRS during December 2017. In connection with the Delinquent Filed Returns, during the period September 2017 through October 2017, the Company received notices that it was being assessed approximately $90,000 of penalties, plus interest (“IRS Penalties”), in connection with the late filing certain information returns that were included as part of the Delinquent Filed Returns. In connection with the notices, the IRS indicated its intent to levy property of the Company if the IRS penalties were not paid as required. During January 2018, the Company requested from the IRS an abatement of the IRS penalties based on reasonable cause. During April 2018, the IRS notified the Company that the IRS penalties for the tax year ended 2011 of $20,000, plus interest, were abated and the request for abatement for the IRS penalties for the tax years ended 2012 – 2015 were denied. The Company is currently appealing the initial determination by the IRS to exclude the IRS penalties for the tax years 2012-2015 in its consideration of abatement. During the period that the appeal is being reviewed and a determination is made by the IRS, the IRS has agreed to put a hold on taking any levy action against the Company for the remaining amounts of the IRS Penalties that are still outstanding. In connection with the notices, the Company has accrued $90,000 of accrued tax penalties on the balance sheet as of October 31, 2017.

12. Capital Stock

12. Capital Stock	12 Months Ended
	Oct. 31, 2017
Equity [Abstract]
Capital Stock	NOTE 12 – CAPITAL STOCK Preferred Stock The Company is authorized to issue 10,000,000 shares of $0.001 par value preferred stock in one or more designated series, each of which shall be so designated as to distinguish the shares of each series of preferred stock from the shares of all other series and classes. The Company’s board of directors is authorized, without stockholders’ approval, within any limitations prescribed by law and the Company’s Articles of Incorporation, to fix and determine the designations, rights, qualifications, preferences, limitations and terms of the shares of any series of preferred stock. Series A Non-Convertible Preferred Stock On November 1, 2016, the Company filed a Certificate of Designation with the Secretary of State of Nevada therein designating out of the 10,000,000 authorized shares of Preferred Stock, a class of Preferred Stock as “Series A Non-Convertible Preferred Stock” consisting of 100 shares (the “ Series A Certificate of Designation “). On March 2, 2017, the Company filed with the Secretary of State of Nevada an amendment to increase the number of shares provided for in the Series A Certificate of Designation from 100 shares to 400 shares. Set forth below is a summary of the Series A Certificate of Designation, as amended. Voting Generally, the outstanding shares of Series A Non-Convertible Preferred Stock shall vote together with the shares of common stock and other voting securities of the Company as a single class and, regardless of the number of shares of Series A Non-Convertible Preferred Stock outstanding, and as long as at least one share of Series A Non-Convertible Preferred Stock is outstanding, such shares shall represent 80% of all votes entitled to be voted at any annual or special meeting of stockholders of the Company or action by written consent of stockholders. Each outstanding share of the Series A Non-Convertible Preferred Stock shall represent its proportionate share of the 80% which is allocated to the outstanding shares of Series A Non-Convertible Preferred Stock. Dividends The holders of shares of Series A Non-Convertible Preferred Stock shall not be entitled to receive any dividends. Ranking The Series A Non-Convertible Preferred Stock shall, with respect to distribution rights on liquidation, winding up and dissolution, (i) rank senior to any of the shares of common stock of the Company, and any other class or series of stock of the Company which by its terms shall rank junior to the Series A Non-Convertible Preferred Stock, and (ii) rank junior to any other series or class of preferred stock of the Company and any other class or series of stock of the Company which by its term shall rank senior to the Series A Non-Convertible Preferred Stock. So long as any shares of Series A Non-Convertible Preferred Stock are outstanding, the Company shall not alter or change any of the powers, preferences, privileges or rights of the Series A Non-Convertible Preferred Stock, without first obtaining the approval by vote or written consent, in the manner provided by law, of the holders of at least a majority of the outstanding shares of Series A Non-Convertible Preferred Stock, as to changes affecting the Series A Non-Convertible Preferred Stock. Issued Shares On November 1, 2016, the Company issued 100 shares of its Series A Non-Convertible Preferred Stock, par value $0.001 per share (“Series A Preferred Stock”) to the CEO. On March 8, 2017, the Company issued 100 shares of the Series A Preferred Stock, to each of the COO, CSO and CFO. In connection with an independent valuation using the “Market Approach”, the Company determined that the value attributable to the Series A Preferred Stock issued were nominal. On February 5, 2018, in connection with the COO’s resignation and termination, the COO agreed to forfeit and the cancellation of the 100 shares of the Series A Preferred Stock previously issued. Effective April 13, 2018, in connection with the Reorganization Plan, the CEO, CFO and CSO each agreed to forfeit and the cancellation their 100 shares of the Series A Preferred Stock previously issued. On June 6, 2018, the Company approved resolutions to cancel and terminate the Series A Preferred Stock designation and file a certificate of amendment with the State of Nevada, withdrawing the designation of the Series A Preferred Stock. On June 14, 2018, the Company filed a Certificate of Withdrawal with the Secretary of State of Nevada thereby withdrawing and terminating all previously issued designations of the Company’s Series A Preferred Stock. As a result of the aforementioned actions, as of June 14, 2018, there were no designations of Series A Preferred Stock authorized or outstanding. Series B Convertible Preferred Stock On November 1, 2016, the Company filed a Certificate of Designation with the Secretary of State of Nevada therein designating out of the 10,000,000 authorized shares of Preferred Stock, a class of Preferred Stock as “Series B Convertible Preferred Stock” consisting of 1,000,000 shares (“Series B Certificate of Designation”). Set forth below is a summary of the Series B Certificate of Designation. Conversion Each holder of Series B Preferred Stock shall have the right, at such holder’s option, at any time or from time to time from and after the day immediately following the date the Series B Preferred Stock is first issued, to convert each share of Series B Preferred Stock into 20 fully-paid and non-assessable shares of common stock. Rank Except as specifically provided below, the Series B Preferred Stock shall, with respect to dividend rights, rights on liquidation, winding up and dissolution, rank junior to the Series A Non-Convertible Preferred Stock of the Company and senior to (i) all classes of common stock of the Company and (ii) any class or series of capital stock of the Company hereafter created (unless, with the consent of the holder(s) of Series B Preferred Stock). Issued Shares On November 1, 2016, the Company entered into a Share Exchange Agreement with Mr. Mitrani. Pursuant to the Share Exchange Agreement, Mr. Mitrani agreed to exchange 20,000,000 shares of his common stock of the Company for an aggregate of 1,000,000 shares Series B Convertible Preferred Stock on a 1-for-20 basis (the “Series B Exchange Agreement”). The terms of the Series B Exchange Agreement were never consummated. On March 8, 2017, the Board and Mr. Mitrani decided to unwind the Series B Exchange Agreement and deem it null and void ab initio. On June 6, 2018, the Company approved resolutions to cancel and terminate the Series B Preferred Stock designations and file a certificate of amendment with the State of Nevada, withdrawing the designation of the Series B Preferred Stock. On June 14, 2018, the Company filed a Certificate of Withdrawal with the Secretary of State of Nevada thereby withdrawing and terminating all previously issued designations of the Company’s Series B Preferred Stock. As a result of the aforementioned actions, as of June 14, 2018, there were no designations of Series B Preferred Stock authorized or outstanding. Common Stock On September 1, 2015, the Company filed a Certificate of Amendment with the Secretary of State of Nevada increasing the amount of authorized common stock from 90,000,000 shares to 250,000,000 shares. On September 17, 2015, the Company completed an eighteen-for-one forward stock split. The consolidated financial statements and notes reflect a retroactive adjustment for the forward stock split. On June 6, 2017, the Board of Directors of the Company and the stockholders holding the Company’s outstanding Series A Preferred Stock, having the voting equivalency of 80% of the outstanding capital stock, approved the filing of an amendment to the Articles of Incorporation of the Company to increase the authorized amount of common stock from 250,000,000 to 750,000,000, without changing the par value of the common stock or authorized number and par value of “blank check” Preferred Stock. On June 19, 2017, the Company filed a Definitive 14C with the SEC regarding the corporate action. On June 22, 2017, the Company filed a Certificate of Amendment to the Company’s Articles of Incorporation with the Secretary of State of Nevada to effectuate the corporate action on July 10, 2017. On June 18, 2018, the Company filed a Certificate of Correction with the Secretary of State of Nevada to effectuate a reverse stock split of one (1) new share for each seventeen (17) shares issued and outstanding as of the record date of May 21, 2018, with resulting fractional shares being rounded up to the nearest whole number, and a reduction in the authorized shares from 750 million to 250 million (the “Reverse Split”). On June 1, 2018, the Company submitted an Issuer Company-Related Notification Form (“June 1 Notification Form”) with FINRA pursuant to Rule 10b-17 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), regarding the Name Change and Reverse Split. However, due to the Company’s delinquency its Exchange Act reports with the SEC by failing to file this Annual Report and its Quarterly Reports for the quarters ended January 31, 2018 and April 30, 2018, FINRA did not announce or effectuate the Name Change or Reverse Split in the marketplace. FINRA has since informed the Company that as a result of the length of time before the Company expects to file its delinquent Exchange Act reports with the SEC, a new Issuer Company-Related Notification Form will be required to be submitted for approval upon the Company becoming current in its Exchange Act filings. Sales of Common Stock From November 2015 to March 2016, the Company sold an aggregate of 364,685 Units to 9 “accredited investors”. Each Unit cost $0.70 and consisted of two shares of common stock, one Class A Warrant and one Class B Warrant. The Company issued a total of 729,370 shares, Class A warrants to purchase 364,685 common shares and Class B warrants to purchase 364,685 common shares for total proceeds of $255,279. The Class A Warrant and Class B Warrant have exercise prices of $0.50 and $1.00, respectively, and have a four-year term. The grant date fair value of the warrants issued in connection with this offering was $379,893. During April 2016, the Company sold 25,000 shares of common stock to an individual for cash proceeds of $5,000. During July 2016, the Company sold 2,200,000 shares of common stock to investors for cash proceeds of $92,000 (net of $18,000 in offering costs). During August 2016, the Company sold 62,500 shares of common stock to an “accredited investor” at $0.08 per share for an aggregate purchase price of $5,000. During September 2016, the Company sold 2,000,000 shares of common stock to an “accredited investor” at $0.05 per share for an aggregate purchase price of $100,000. During January 2017, the Company sold 100,000 shares of common stock to an “accredited investor” at $0.05 per share for an aggregate purchase price of $5,000. During January 2017 and February 2017, the Company sold an aggregate of 600,000 Units and 300,000 Units, respectively. Each Unit cost $0.10 and consisted of two shares of common stock, one Class A Warrant and one Class B Warrant. The Company issued a total of 1,800,000 common shares, Class A warrants to purchase 900,000 common shares and Class B warrants to purchase 900,000, common shares. The Class A Warrant and Class B Warrant have exercise prices of $0.075 and $0.150, respectively, and have a three-year term. The aggregate grant date fair value of the warrants issued in connection with this offering was $33,480. The total proceeds received from the above sales occurring in January 2017 and February 2017 were $60,000 and $30,000, respectively. During February 2017, the Company sold 250,000 shares of common stock to a related party at $0.04 per share for an aggregate purchase price of $10,000. On March 8, 2017, in consideration for consulting services rendered to the Company and Mint Organics, Inc., the Board approved the issuance of 100,000 shares of unregistered common stock valued at $0.03 per share, the closing price of the common stock of the Company on that date, to a consultant. The Company recorded $3,000 of stock-based compensation expense based on the grant date fair value of these shares. On March 29, 2017, in connection with the terms of the SPA, the Company issued the Agent, Werber and Bothwell a total of 2,000,000, 1,000,000 and 1,000,000 common shares of the Company, respectively, valued in the aggregate at $63,680, based on the closing price of the common stock of the Company on the date the stock was issued. On May 17, 2017, in connection with the Taddeo Agreement, the Company granted Taddeo 1,000,000 shares of unregistered common stock. The value of the stock grant was determined to be $12,000 based on the closing price of the common stock of the Company on the date of grant ($0.12 per share). The shares vest on the date Mint Organics, through one of its subsidiaries, obtains a license from a state to dispense cannabis or December 31, 2017, whichever is earlier, and provided that Taddeo’s employment has not been terminated prior to the time the vesting conditions have been met. The Company has recorded amortization expense totaling $8,800 for the period from date the stock grant was issued through October 31, 2017 as additional stock-based compensation. During January 2018, the Company sold 4,062,500 shares of common stock to four “accredited investors” at $0.016 per share for an aggregate purchase price of $65,000. In connection with the Sale of the ANU assets on February 5, 2018, and the immediate resignation and termination of the Company’s Chief Operating Officer, the Chief Operating Officer agreed to forfeit 53,300,000 warrants to purchase shares of the Company’s common stock held at the time of the resignation and the Company agreed to grant the Chief Operating Officer 7,500,000 shares of newly issued common stock of the Company valued at $0.011 per share, the closing price of the common stock of the Company on the date of the Sale. The Company will record $82,500 of stock-based compensation expense based on the grant date fair value of these shares during the period that the shares were granted. In connection with the Sale of the ANU assets on February 5, 2018, and the immediate resignation and termination of the Company’s Chief Technology Officer, the Chief Technology Officer agreed to forfeit 23,850,000 warrants to purchase shares of the Company’s common stock held at the time of the resignation and the Company agreed to grant the Chief Technology Officer 7,500,000 shares of newly issued common stock of the Company valued at $0.011 per share, the closing price of the common stock of the Company on the date of the Sale. The Company will record $82,500 of stock-based compensation expense based on the grant date fair value of these shares during the period that the shares were granted. During February 2018, the Company sold 1,250,000 shares of common stock to an “accredited investor” at $0.016 per share for an aggregate purchase price of $20,000. The proceeds were used for working capital. During March 2018, the Company sold 313,500 shares of common stock to an “accredited investor” at $0.016 per share for an aggregate purchase price of $5,000. The proceeds were used for working capital. During April 2018, the Company sold 625,000 shares of common stock to two “accredited investors” at $0.016 per share for an aggregate purchase price of $10,000. The proceeds were used for working capital. As described in Note 5, effective April 13, 2018 in connection with the Reorganization Plan, the Company agreed to issue to MBA an aggregate of 222,425,073 shares of its common stock, representing 51% of the outstanding shares of the common stock of the Company on fully-diluted basis, for $0.001 per share (or an aggregate of $222,425), in consideration for MBA’s founder and Chief Executive Officer, Mr. Manuel Iglesias’ agreement to serve as the Company’s Chief Executive Officer and a member of the Board of the Company. In connection with the Reorganization Plan, The CFO and CSO each agreed to exercise on a cashless basis all of their warrants to purchase 53,300,000 and 23,850,000 shares of common stock of the Company, respectively. Based on the closing price of the Company’s common stock on the Effective Date of $0.016 per share and the warrant exercise price of $0.001 per share, the CFO and CSO were required to use 4,675,439 and 2,092,105 shares of common stock received from the exercise of the warrants, respectively, to pay for the exercise price for exercising all of the warrants. Effective April 13, 2018, the CFO and CSO were each granted 4,675,439 and 2,092,105 shares of common stock of the Company, respectively valued at $0.016 per share based on the closing price of the common stock of the Company on the effective date of the grant. The newly granted shares vest immediately and the Company will record stock-based compensation of $74,807 and $33,474, respectively, during the period that the shares were granted.

13. Warrants

13. Warrants	12 Months Ended
	Oct. 31, 2017
Warrants
Warrants	NOTE 13 – WARRANTS During the year ended October 31, 2016, the Company issued 729,370 warrants in connection with common stock offerings and valued the warrants on the dates of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate from 1.22% to 1.57%, (2) term of 4 years, (3) expected stock volatility from 97% to 100%, and (4) expected dividend rate of 0%. All of the warrants vested immediately. The grant date fair value of the warrants issued during the year ended October 31, 2016 was $379,893. In connection with the Executive Employments Agreements dated November 4, 2016 (see Note 14), the Company granted the following warrants to each executive as described below: Bothwell: a warrant to purchase, on a cashless basis, up to 31,800,000 shares of common stock of the Company for $0.06 per share, the closing price of the Company’s common stock on the date of the grant, exercisable in accordance with the vesting schedule below until the 10th anniversary of the date of issuance: (a) Immediately on the Effective Date, 50% of the Warrant shall vest and the remaining 50% shall vest in 18 equal monthly installments beginning on November 30, 2016 or until Bothwell no longer remains employed by the Company, whichever is earlier. Notwithstanding the foregoing vesting schedule, the unvested portion of the Warrant shall be accelerated upon the achievement of the milestones set forth below, to the satisfaction of the Board in its sole discretion and contingent upon Mr. Bothwell’s continued employment at the time of consummation: 1. 25% upon the consummation of an equity or debt financing and resulting in gross proceeds of at least $300,000, including, but not limited to, the currently contemplated financing in connection with the SPA; and 2. 25% upon the consummation of a series of equity or debt financings resulting in aggregate process gross proceeds in excess of $1,500,000. The Company valued the above warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate of 1.79%, (2) term of 10 years, (3) expected stock volatility of 152%, and (4) expected dividend rate of 0%. The grant date fair value of the warrants issued was $1,879,380 of which $1,722,765 has been amortized during the year ended October 31, 2017, and the remaining unamortized costs will be expensed pro rata as the warrants vest. Werber: a warrant to purchase, on a cashless basis, up to 31,800,000 shares of common stock of the Company for $0.06 per share, the closing price of the Company’s common stock on the date of the grant, fully vested at the time of the grant and exercisable until the 10th anniversary of the date of issuance. The Company valued the above warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate of 1.79%, (2) term of 10 years, (3) expected stock volatility of 152%, and (4) expected dividend rate of 0%. The grant date fair value of the warrants issued was $1,879,380 of which $1,879,380 has been amortized during the year ended October 31, 2017. M. Mitrani: a warrant to purchase, on a cashless basis, up to 10,000,000 shares of common stock of the Company for $0.06 per share, the closing price of the Company’s common stock on the date of the grant, fully vested at the time of the grant and exercisable until the 10th anniversary of the date of issuance. The Company valued the above warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate of 1.79%, (2) term of 10 years, (3) expected stock volatility of 152%, and (4) expected dividend rate of 0%. The grant date fair value of the warrants issued was $591,000 of which $591,000 has been amortized during the year ended October 31, 2017. During January 2017 and February 2017, the Company issued 1,200,000 and 600,000 warrants, respectively, in connection with common stock offerings and valued the warrants on the dates of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate 1.43% to 1.50%, (2) term of 3 years, (3) expected stock volatility of 106%, and (4) expected dividend rate of 0%. All of the warrants vested immediately. The grant date fair value of the warrants issued during January 2017 and February 2017 was $22,320 and $11,160, respectively. In connection with the Participation Agreement, on March 8, 2017, the Company issued warrants to Mr. Peter Taddeo, a member of the Board and the Chief Executive Officer and a director of both Mint Organics and Mint Organics Florida and Mr. Wayne Rohrbaugh, the Chief Operating Officer and a director of both Mint Organics and Mint Organics Florida, to each purchase 150,000 shares of common stock of the Company at an exercise price of $0.15 per share, exercisable from the date of issuance until the third anniversary date of the date of issuance. The Company valued the above warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate of 1.38%, (2) term of 3 years, (3) expected stock volatility of 106%, and (4) expected dividend rate of 0%. The grant date fair value of the warrants issued was $4,770. On March 8, 2017, in connection with Mr. Suddarth’s employment agreement, the Company granted Mr. Suddarth a warrant to purchase, on a cashless basis, 23,850,000 shares of the Company’s common stock at an exercise price of $0.02 per share, the closing price of common stock of the Company on March 8, 2017, exercisable in accordance with the vesting schedule below until the 10 th (a) Immediately on the Effective Date, 50% of the Warrant shall vest and, thereafter, the remaining 50% shall vest in 18 equal monthly installments beginning on March 31, 2017 or until Suddarth no longer remains employed by the Company, whichever is earlier. (b) Notwithstanding the foregoing vesting schedule, the unvested portion of the Warrant shall be accelerated upon the achievement of the milestones set forth below, to the satisfaction of the Board in its sole discretion and contingent upon Mr. Suddarth’s continued employment at the time of consummation: 1. 25% for the commercial availability of a sheet type human amnion product 2. 15% for the third commercially available product; and 3. 10% for the fourth commercially available product The Company valued the above warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate of 2.57%, (2) term of 10 years, (3) expected stock volatility of 153%, and (4) expected dividend rate of 0%. The grant date fair value of the warrants issued was $469,845 of which $469,845 has been amortized during the year ended October 31, 2017. On March 8, 2017, the Board of the Company granted warrants to purchase shares of common stock of the Company on a cashless basis to the following executive officers and directors of the Company: Executive Officer Warrants: Dr. Bruce Werber (Chief Operating Officer and Director) 21,500,000 Ian T. Bothwell (Chief Financial Officer and Director) 21,500,000 Dr. Maria Ines Mitrani (Chief Science Officer and Director) 13,850,000 TOTAL 56,850,000 The foregoing warrants are exercisable for $0.02 per share, the closing price of common stock of the Company on March 8, 2017, and are exercisable from the date of issuance until the 10th anniversary of the date of issuance. The Company valued the above warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate of 2.57%, (2) term of 10 years, (3) expected stock volatility of 153%, and (4) expected dividend rate of 0%. The grant date fair value of the warrants issued was $1,119,945 of which $1,119,945 has been amortized during the year ended October 31, 2017. A summary of warrant activity for the years ended October 31, 2016 and 2017 are presented below. Number of Shares Weighted-average Exercise Price Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at October 31, 2015 1,008,114 $ 0.75 3.78 $ – Granted 729,370 $ 0.75 4.00 $ – Exercised – $ – – – Expired/Forfeited – $ – – – Outstanding and exercisable at October 31, 2016 1,737,484 $ 0.75 3.01 $ – Number of Shares Weighted-average Exercise Price Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at October 31, 2016 1,737,484 $ 0.75 3.01 $ – Granted 156,400,000 $ 0.05 9.90 $ – Exercised – $ – – – Expired/Forfeited – $ – – – Outstanding at October 31, 2017 158,137,484 $ 0.05 9.02 $ – Exercisable at October 31, 2017 155,487,484 $ 0.05 9.02 $ – In connection with the Sale of ANU assets on February 5, 2018, and the immediate resignation and termination of the Company’s Chief Operating Officer, the Chief Operating Officer agreed to forfeit 53,300,000 warrants to purchase shares of the Company’s common stock held at the time of the resignation and the Company agreed to grant the Chief Operating Officer 7,500,000 shares of newly issued common stock of the Company. In connection with the Sale of ANU assets on February 5, 2018, and the immediate resignation and termination of the Company’s Chief Technology Officer, the Chief Technology Officer agreed to forfeit 23,850,000 warrants to purchase shares of the Company’s common stock held at the time of the resignation and the Company agreed to grant the Chief Technology Officer 7,500,000 shares of newly issued common stock of the Company. In connection with the amendment to the Chief Financial Officer’s employment agreement on April 6, 2018, the terms of the remaining warrants previously granted to the Chief Financial Officer were modified to provide that in the event of an occurrence of a change in control or termination of the employment (as defined in the agreement), pursuant to the terms thereof, the exercise price for all outstanding warrants granted to the Chief Financial officer to purchase common stock of the Company during the term of his employment agreement shall be reduced to $0.001 per share. The Company will value the modification to the terms of the exercise price for the Chief Financial Officer’s warrants as of the date of the amendment using the Black-Scholes option pricing model and record the expense upon such time that the terms associated with the reduction in exercise prices are met (see Note 5). In connection with the amendment to the Chief Science Officer’s employment agreement on April 6, 2018, the terms of the remaining warrants previously granted to the Chief Science Officer were modified to provide that in the event of an occurrence of a change in control or termination of the employment (as defined in the agreement), pursuant to the terms thereof, the exercise price for all outstanding warrants granted to the Chief Science Officer to purchase common stock of the Company during the term of her employment agreement shall be reduced to $0.001 per share. The Company will value the modification to the terms of the exercise price for the Chief Science Officer’s warrants as of the date of the amendment using the Black-Scholes option pricing model and record the expense upon such time that the terms associated with the reduction in exercise prices are met (see Note 5). In connection with the Reorganization Plan, The CFO and CSO each agreed to exercise on a cashless basis all of their warrants to purchase 53,300,000 and 23,850,000 shares of common stock of the Company, respectively. Based on the closing price of the Company’s common stock on the Effective Date of $0.016 per share and the warrant exercise price of $0.001 per share, the CFO and CSO were required to use 4,675,439 and 2,092,105 shares of common stock received from the exercise of the warrants, respectively, to pay for the exercise price for exercising all of the warrants.

14. Commitments and Contingenci

14. Commitments and Contingencies	12 Months Ended
	Oct. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 14 – COMMITMENTS AND CONTINGENCIES Employment Agreements On August 1, 2015, the Company entered into employment agreements with two employees. Each employment agreement contained the following terms: (a) if net monthly sales generated by the Company are less than $50,000 and net profit margin on the aggregate sales is less than 35%, no base salary is payable; (b) if net monthly sales generated by the Company are $50,000 or more but less than $75,000 and net profit margin on the aggregate sales is less than 35%, the base salary shall be $6,000; (b) if net monthly sales generated by the Company are $75,000 or more but less than $100,000 and net profit margin on the aggregate sales is less than 35%, the base salary shall be $9,000; and (d) if net monthly sales generated by the Company are $100,000 or more and net profit margin on the aggregate sales is less than 35%, the base salary shall be $15,000. In addition, the Company agreed to issue each employee 225,000 restricted shares of common stock of the Company upon achieving certain milestones. On November 17, 2015, the Company executed a Termination Agreement and Mutual Release in connection with both of the above-mentioned employment agreements. The parties released each other from any claims or liabilities one to the other, and the employment agreements between the Company and each of the employees were terminated in their entirety. The Company was not required to issue any of the shares of common stock provided for in the agreements or make any settlement payments in connection with the terminations. Executive Employment Agreements Effective November 4, 2016, the Company entered into executive employment agreements with Albert Mitrani, the CEO; the CEO’s wife Maria Mitrani, the Chief Science Officer (“CSO”); Bruce Werber, the Chief Operating Officer (“COO”); and Ian Bothwell, the Chief Financial Officer (“CFO”). On March 8, 2017, the Company entered into an executive employment agreement with Terrell Suddarth, the Chief Technology Officer (“CTO”), and amended the CSO’s, the COO’s and CFO’s executive employment agreements. On April 6, 2018, the Company amended the CFO’s and CSO’s executive employment agreements (collectively the CEO, CSO, COO, CFO’s and CTO’s executive employment agreements, as amended, are referred to as the “Executive Agreements”). The terms provided for in the each of the Executive Agreements are summarized below: CEO Mr. Mitrani shall serve as the Company’s CEO and Chairman of the Board of Directors of the Company. The employment term shall be for five years, unless terminated earlier pursuant to the terms of the agreement, and thereafter deemed to be automatically extended, upon the same terms and conditions, for successive periods of five years, unless either party provides written notice of its intention not to extend the term at least 90 days prior to the applicable renewal date. The CEO’s base annual salary is $360,000, which shall accrue commencing October 1, 2016 and shall be payable upon the Company generating sufficient net revenue or obtaining sufficient third party financing. The base salary shall be reviewed at least annually by the Board and the Board may, but shall not be required to, increase the base salary during the employment term. In connection with the execution of the agreement, the Company agreed to pay the CEO a $100,000 signing bonus which shall be accrued and paid by the Company upon the Company having sufficient cash flow. In addition, the agreement provided for the settlement of unpaid expenses and prior salary of approximately $120,000 to be paid upon the earliest reasonably practicable time that there is sufficient working capital as determined by the Board. The agreement also contains terms regarding eligibility for future annual bonuses, annual equity awards under the Company’s equity plan, if any, fringe benefits and perquisites consistent with the practices of the Company (including health and dental insurance, an automobile expense allowance of $2,500 per month plus all expenses related to the maintenance, repair and operation of such automobile, reimbursement for all reasonable and necessary out-of-pocket business, entertainment and travel expenses incurred by the CEO in accordance with the Company's expense reimbursement policies and procedures and a personal life insurance policy of up to $2,000,000. The Company may terminate the agreement at any time with or without “Cause” and the CEO may resign at any time with or without “Good Reason” (as defined in the agreement). The nature of the obligations owing to the CEO upon termination is more fully described in the agreement. See discussion below regarding the termination of the agreement and execution of a new employment agreement with the CEO on April 13, 2018. COO Mr. Werber shall serve as the Company’s COO and member of the Board of Directors of the Company. The employment term shall be for three years, unless terminated earlier pursuant to the terms of the agreement, and thereafter deemed to be automatically extended, upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term at least 90 days prior to the applicable renewal date. The COO’s base annual salary is $360,000, which shall accrue commencing October 1, 2016 and shall be payable upon the Company generating sufficient net revenue or obtaining sufficient third party financing. The base salary shall be reviewed at least annually by the Board and the Board may, but shall not be required to, increase the base salary during the employment term. In connection with the execution of the agreement, the Company agreed to pay the COO a $35,000 signing bonus which shall be accrued and paid by the Company upon the Company having sufficient cash flow. The agreement also contains terms regarding eligibility for future annual bonuses, annual equity awards under the Company’s equity plan, if any, fringe benefits and perquisites consistent with the practices of the Company (including health and dental insurance, an automobile expense allowance of $650 per month, reimbursement for all reasonable and necessary out-of-pocket business, entertainment and travel expenses incurred by the COO in accordance with the Company's expense reimbursement policies. The Company may terminate the agreement at any time with or without “Cause” and the COO may resign at any time with or without “Good Reason” (as defined in the agreement). The nature of the obligations owing to the COO upon termination is more fully described in the agreement. In connection with the execution of the agreement, the Company granted the COO a warrant to purchase, on a cashless basis, up to 31,800,000 shares of common stock of the Company for $0.06 per share, the closing price of the Company’s common stock on the effective date, fully vested at the time of the grant and exercisable until the 10th anniversary of the date of issuance (see Note 13). See discussion below regarding the termination of the agreement with the COO on February 5, 2018. CFO Mr. Bothwell shall serve as the Company’s CFO and member of the Board of Directors of the Company. The employment term shall be for three years, unless terminated earlier pursuant to the terms of the agreement, and thereafter deemed to be automatically extended, upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term at least 90 days prior to the applicable renewal date. The CFO’s base annual salary is $360,000, which shall accrue commencing October 1, 2016 and shall be payable upon the Company generating sufficient net revenue or obtaining sufficient third party financing. The base salary shall be reviewed at least annually by the Board and the Board may, but shall not be required to, increase the base salary during the employment term. In connection with the execution of the agreement, the Company agreed to pay the CFO a $35,000 signing bonus which shall be accrued and paid by the Company upon the Company having sufficient cash flow. The agreement also contains terms regarding eligibility for future annual bonuses, annual equity awards under the Company’s equity plan, if any, fringe benefits and perquisites consistent with the practices of the Company (including health and dental insurance, an automobile expense allowance of $650 per month, reimbursement of office related expenses up to $2,500 per month, reimbursement for all reasonable and necessary out-of-pocket business, entertainment and travel expenses incurred by the CFO in accordance with the Company's expense reimbursement policies. The Company may terminate the agreement at any time with or without “Cause” and the CFO may resign at any time with or without “Good Reason” (as defined in the agreement). The nature of the obligations owing to the CFO upon termination is more fully described in the agreement. In connection with the execution of the agreement, the Company granted the CFO a warrant to purchase, on a cashless basis, up to 31,800,000 shares of common stock of the Company for $0.06 per share, the closing price of the Company’s common stock on the effective date, exercisable in accordance with the vesting schedule as described in the agreement until the 10th anniversary of the date of issuance (see Note 13). On April 6, 2018, the Company amended the CFO’s employment agreement, which provided among other things, that in the event of an occurrence of a change in control or termination of the employment (as defined in agreement) pursuant to the terms thereof, the exercise price for all outstanding warrants granted to the CFO to purchase common stock of the Company during the term of the agreement shall be reduced to $0.001 per share. In addition, Mr. Bothwell’s employment agreement was amended to increase the initial term and the automatic renewal term provided for in the employment agreement from three years to five years, increased the amount of automobile expense allowance and removed the cap for the reimbursement of office related expenses. See discussion below regarding the termination of the agreement and execution of a new employment agreement with the CFO on April 13, 2018. CSO Dr. Maria Ines Mitrani shall serve as the Company’s CSO and member of the Board of Directors of the Company. The employment term shall be for five years, unless terminated earlier pursuant to the terms of the agreement, and thereafter deemed to be automatically extended, upon the same terms and conditions, for successive periods of five years, unless either party provides written notice of its intention not to extend the term at least 90 days prior to the applicable renewal date. The CSO’s base annual salary is $250,000 (subsequently amended to $300,000 on March 8, 2017), which shall accrue commencing October 1, 2016 and shall be payable upon the Company generating sufficient net revenue or obtaining sufficient third party financing. The base salary shall be reviewed at least annually by the Board and the Board may, but shall not be required to, increase the base salary during the employment term. In connection with the execution of the agreement, the Company agreed to pay the CSO a $50,000 signing bonus which shall be accrued and paid by the Company upon the Company having sufficient cash flow. In addition, the agreement provided for the settlement of unpaid expenses and prior consulting fees owed to MariLuna LLC, an entity owned by the CSO, of approximately $84,000 to be paid upon the earliest reasonably practicable time that there is sufficient working capital as determined by the Board. The agreement also contains terms regarding eligibility for future annual bonuses, annual equity awards under the Company’s equity plan, if any, fringe benefits and perquisites consistent with the practices of the Company (including health and dental insurance, an automobile expense allowance of $1,000 per month plus all expenses related to the maintenance, repair and operation of such automobile and reimbursement for all reasonable and necessary out-of-pocket business, entertainment and travel expenses incurred by the CSO in accordance with the Company's expense reimbursement policies and procedures. The Company may terminate the agreement at any time with or without “Cause” and the CSO may resign at any time with or without “Good Reason” (as defined in the agreement). The nature of the obligations owing to the CSO upon termination is more fully described in the agreement. In connection with the execution of the agreement, the Company granted the CSO a warrant to purchase, on a cashless basis, up to 10,000,000 shares of common stock of the Company for $0.06 per share, the closing price of the Company’s common stock on the effective date, fully vested at the time of the grant and exercisable until the 10th anniversary of the date of issuance (see Note 13). On April 6, 2018, the Company amended the CSO’s employment agreement, which provided among other things, that in the event of an occurrence of a change in control or termination of the employment (as defined in agreement) pursuant to the terms thereof, the exercise price for all outstanding warrants granted to the CSO to purchase common stock of the Company during the term of the agreement shall be reduced to $0.001 per share. See discussion below regarding the termination of the agreement and execution of a new employment agreement with the CSO on April 13, 2018. CTO Mr. Suddarth shall serve as the Company’s CTO and member of the Board of Directors of the Company. The employment term shall be for three years, unless terminated earlier pursuant to the terms of the agreement, and thereafter deemed to be automatically extended, upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term at least 90 days prior to the applicable renewal date. The CTO’s base annual salary is $300,000, which shall accrue commencing October 1, 2016 and shall be payable upon the Company generating sufficient net revenue or obtaining sufficient third party financing. The base salary shall be reviewed at least annually by the Board and the Board may, but shall not be required to, increase the base salary during the employment term. In connection with the execution of the agreement, the Company agreed to pay the CTO a $35,000 signing bonus which shall be accrued and paid by the Company upon the Company having sufficient cash flow. The agreement also contains terms regarding eligibility for future annual bonuses, annual equity awards under the Company’s equity plan, if any, fringe benefits and perquisites consistent with the practices of the Company (including health and dental insurance, an automobile expense allowance of $650 per month, and reimbursement for all reasonable and necessary out-of-pocket business, entertainment and travel expenses incurred by the CTO in accordance with the Company's expense reimbursement policies. The Company may terminate the agreement at any time with or without “Cause” and the CTO may resign at any time with or without “Good Reason” (as defined in the agreement). The nature of the obligations owing to the CTO upon termination is more fully described in the agreement. In connection with the execution of the agreement, the Company granted the CTO a warrant to purchase, on a cashless basis, up to 23,850,000 shares of common stock of the Company for $0.02 per share, the closing price of the Company’s common stock on the effective date, exercisable in accordance with the vesting schedule as described in the agreement until the 10th anniversary of the date of issuance (see Note 13). See discussion below regarding the termination of the agreement with the CTO on February 5, 2018. Termination Of Executive Employment Agreements In connection with Sale (see Note 4), Werber and Suddarth each entered into a Separation and General Release Agreement with the Company effective upon the closing of the Sale which provided for the immediate resignation of Werber and Suddarth of all their respective executive and Board of Director positions held with the Company and/or any of the Company’s subsidiaries, and the termination and settlement of all obligations of each party to the other pursuant to the respective employment agreements, including the release of all rights the Company may have held in any intellectual property of Werber and Suddarth and any non-compete restrictions on Werber and Suddarth. In connection with such releases, Werber and Suddarth each agreed to forfeit all warrants previously granted and outstanding (a total of 77,150,000 warrants to purchase shares of common stock of the Company), forfeit any and all accrued and unpaid amounts owing under the employment agreements for past due wages, benefits, severance obligations, unreimbursed expenses and any other obligations owing to one another as of the date of the Sale in exchange for a grant of 7,500,000 shares of restricted common stock of the Company to each of Werber and Suddarth (the grant date fair value of the newly issued shares issued to each of Werber and Suddarth was $82,500). Effective April 13, 2018, in connection with Reorganization Plan described in Note 5, Manuel Iglesias replaced Albert Mitrani as the Chief Executive Officer of the Company, Ian Bothwell resigned from the Board of Directors of the Company and Maria Mitrani resigned from the Board of Directors of the Company. In addition, effective April 13, 2018, Albert Mitrani, Ian Bothwell, and Maria Mitrani, each agreed to terminate their respective executive employment agreements, dated November 4, 2016, as amended, in favor of new employment agreements (“New Executive Employment Agreements”) under the terms described below. In addition, in connection with the termination of the aforementioned agreements, Albert Mitrani, Ian Bothwell and Maria Mitrani each agreed to release the Company for all amounts owing to them for unpaid salaries through the Effective Date and advances and/or expenses incurred prior to December 31, 2017. New Executive Employment Agreements On April 23, 2018, the Company entered into new employment agreements, effective as of April 13, 2018 (“New Executive Employment Agreements”), with each of Albert Mitrani, Ian Bothwell and Maria Mitrani (each, an “Executive”). Pursuant to the Albert Mitrani’s New Executive Employment Agreement, Mr. Mitrani shall serve as the Company’s President. Mr. Mitrani’s base annual salary is $162,500, which shall accrue commencing Effective Date and shall be payable in equal semi-monthly installments, commencing May 1, 2018, in arrears. The base salary shall be reviewed at least annually by the Board and the Board may, but shall not be required to, increase the base salary during the Employment Term. Pursuant to Ian Bothwell’s New Employment Agreement, Mr. Bothwell shall continue to serve as the Company’s Chief Financial Officer. Mr. Bothwell’s base annual salary is $162,500, which shall accrue commencing Effective Date and shall be payable in equal semi-monthly installments, commencing May 1, 2018, in arrears. The base salary shall be reviewed at least annually by the Board and the Board may, but shall not be required to, increase the base salary during the Employment Term. Pursuant to Maria Mitrani’s New Employment Agreement, Dr. Mitrani shall continue serving as the Company’s Chief Science Officer. Dr. Mitrani’s base annual salary is $162,500, which shall accrue commencing Effective Date and shall be payable in equal semi-monthly installments, commencing May 1, 2018, in arrears. The base salary shall be reviewed at least annually by the Board and the Board may, but shall not be required to, increase the base salary during the Employment Term. Term The term of each New Employment Agreement commences as of the Effective Date and continues until December 31, 2020 (Mr. Bothwell) or December 31, 2023 (Mr. Mitrani and Ms. Mitrani) (“Initial Term”), unless terminated earlier pursuant to the terms of the New Employment Agreement; provided that Unpaid Advances All unpaid advances by the Executive to the Company prior to January 1, 2018 and all unreimbursed expenses of Executive incurred prior to January 1, 2018 are forgiven and shall be written off by Executive. The Company shall repay the unpaid advances subsequent to December 31, 2017, and the unreimbursed expenses incurred subsequent to December 31, 2017, on May 15, 2018. Fringe Benefits and Perquisites During the Employment Term, each Executive shall be entitled to fringe benefits and perquisites consistent with the practices of the Company, and to the extent the Company provides similar benefits or perquisites (or both) to similarly situated executives of the Company. Termination The Company may terminate the New Employment Agreement at any time for good cause, as defined in the New Employment Agreement, including, the Executive’s death, disability, Executive’s willful and international failure or refusal to follow reasonable instructions of the Company’s Board of Directors, reasonable and material policies, standards and regulations of the Company’s Board of Directors or management. Leases Ethan NY On September 3, 2015, Ethan NY entered into a five-year lease agreement (“Ethan Lease”) for a store located in New York City, New York. The Ethan Lease commenced on October 1, 2015. Under the terms of the Ethan Lease, Ethan NY provided an $18,585 security deposit and a former employee of Ethan NY provided a personal guaranty for a portion of the amounts due under the Ethan Lease. During June 2016, Ethan NY exited from its leased premises. Under the terms of the Ethan Lease, minimum monthly lease payments of $9,500 per month were to commence in December 2015 through October 2020. Ethan NY has not made any of the required minimum monthly lease payments as required including approximately $66,500 and $104,785 for the seven months ended June 30, 2016 and the eleven months ended October 31, 2016, respectively. The total amount of minimum lease payments that Ethan NY is obligated to pay pursuant to this 5-year lease is $586,242 (excluding late fees and interest provided for under the Ethan Lease). The lease payments pursuant to the Ethan Lease were as follows: Year Ended Minimum October 31, Rent 2016 $ 104,785 2017 117,714 2018 121,245 2019 124,882 2020 117,616 2021 – Total $ 586,242 All of Ethan NY’s obligations under the Ethan Lease are recourse only to the assets at Ethan NY, except for certain obligations under the Ethan Lease that were guaranteed by a former employee. Under the terms of the Ethan Lease, the obligations of Ethan NY for future rents are to be mitigated based on the amount of any future rents that are received for the rental of the leased premises to other tenants during the initial term. During August 2016, Ethan NY received confirmation that the leased premises had been leased to another tenant. In connection with the termination of the Ethan Lease, Ethan NY has made several unsuccessful attempts to contact the landlord for the purpose of obtaining a settlement and release for any amounts that the landlord may claim are owing under the Ethan Lease, if any. Ethan NY is not aware of any claim pending or threatened in connection with the Ethan Lease. At October 31, 2016 and 2017, Ethan NY has recorded in liabilities of discontinued operations the amount of rent obligations through June 30, 2016 and a reserve for estimated losses in connection with termination of the Ethan Lease of $76,000 and $25,905, respectively. In addition, in connection with the termination of the Ethan Lease, Ethan NY recorded in its loss from discontinued operations for the year ended October 31, 2016 the loss of the $18,585 security deposit made in connection with the execution of the Ethan Lease that is non-returnable to Ethan NY upon the occurrence of certain defined events prescribed under the Ethan Lease and the impairment loss of $5,463 associated with the remaining net amounts of furniture & fixtures and leasehold improvements that were remaining on the books and are not recoverable in connection with the termination of the Ethan Lease and the closing of the store location. Anu Life Sciences, Inc. In connection with the Company’s decision to relocate its existing placental tissue bank processing laboratory in Miami, Florida, on May 23, 2017, our wholly-owned subsidiary, Anu Life Sciences Inc. a Florida corporation (“ANU”), entered into a five-year lease agreement (“Lab Lease”) for an approximately 3,500 square foot laboratory and administrative office facility in Sunrise, Florida. The Lab Lease is effective July 1, 2017 and expires on June 30, 2022, and provided for the ability of ANU to move into the premises beginning June 20, 2017. In connection with the Lab Lease, ANU provided a $37,275 security deposit of which $18,638 is to be returned to ANU after the 2 nd Year Ended Minimum October 31, Rent 2018 $ 95,421 2019 99,663 2020 109,049 2021 111,782 2022 75,758 Total $ 491,673 The minimum lease payments described above exclude applicable Florida sales tax and additional rents as may be required under the terms of the Lab Lease. In accordance with the terms of the lease for the Company’s existing laboratory facility, the Company provided its notice of termination and as of June 20, 2017, completed the relocation of the lab facilities to the Sunrise leased premises. As described in Note 4, in connection with the Sale, ANU sold or transferred to Vera its right, title and interest in the Lab Lease (including the associated security deposits) and all leasehold improvements. Termination of Contract On February 23, 2016, the Distribution Agreement, dated August 11, 2015, between Amnio Technology, LLC (“Amnio Technology”) and the Company’s wholly-owned subsidiary, BD Source, was terminated by Amnio Technology. Pursuant to the Distribution Agreement, Amnio Technology had engaged BD Source pursuant to the Distribution Agreement in connection with the marketing, sales and distribution of certain of Amnio Technology's products. Amnio Technology is engaged in the business of human tissue procurement, processing and distribution to customers and third party distributors. Amnio Technology terminated the Distribution Agreement due to BD Source's non-payment of the outstanding balance of $4,815 under the Distribution Agreement. BD Source has since paid such balance and believes that all obligations owed to Amnio Technology have been satisfied. Convertible Equity Securities Conversion of Notes issued in connection with the SPA In connection with the SPA, at any time after the six (6) month anniversary of the closing date and until the Note is no longer outstanding, any outstanding principal portion of the Note shall be convertible, in whole or in part, into shares of common stock of the Company at the option of each Purchaser (subject to the conversion limitations set forth in the SPA). The Company performed an independent valuation (using “Monte Carlo Simulation Models”) of the underlying value attributable to the fair value of the embedded derivatives liabilities associated with the Notes at the issuance date (the Notes contain full ratchet reset provisions and variable market based conversion derivative features) and determined that the fair value of the derivative liabilities associated with the Note was $759,569 (the derivative liability will be marked-to-market each quarter with the change in fair value recorded in the income statement). As of October 31, 2017, the amounts owed under the SPA, including original issue discount and accrued interest was $536,820. In connection with the Sale, (see Note 4), the Notes were repaid in full and all contingency conversion rights associated with Notes were no longer outstanding. The Company will write-off any remaining balance outstanding of the derivative liabilities as of the date of the Sale. Series A Preferred Stock of Mint Organics Inc. As more fully described in Note 15, each share of the Mint Series A Preferred Stock shall automatically convert into 1.5 shares of Class B Common stock of Mint Organics upon the earlier of (a) the fifth anniversary of the date such share of Mint Series A Preferred Stock was issued; or (b) Mint Organics’ receipt of the necessary licenses and permits required to operate business operations in the medical cannabis industry. In addition, commencing on the first anniversary of the issuance date and within the 90-day period thereafter, each holder of the Mint Series A Preferred Stock shall have the right, but not the obligation, to convert some or all of such holder’s shares of Mint Series A Preferred Stock (or Class B Common Stock equivalent) into unregistered shares, par value $0.001 per share, of common stock of Organicell, based on the Stated Value divided by the average trading price of Organicell common stock for the ten trading days prior the conversion date. Notwithstanding the foregoing, the number of shares of Class B Common Stock issuable upon the conversion of the outstanding Mint Series A Preferred Stock shall be adjusted to ensure that the outstanding Class B Common Stock represents 45% of the outstanding capital stock of Mint Organics (based on conversion of 300 shares of the Mint Series A Preferred Stock or pro rata portion thereof). On April 6, 2018, in connection with Mr. Taddeo’s resignation, the Company and Mr. Taddeo entered into a Share Purchase and General Release Agreement whereby the Company agreed to purchase from Mr. Taddeo his 150 shares of Mint Series A Convertible Preferred Stock of Mint Organics for an aggregate purchase price of $40,000. (see Note 15). Effective May 14, 2018, the conversion rights for the holders of the Mint Series A Preferred Stock (or Class B Common Stock equivalent) to convert into unregistered shares, par value $0.001 per share, of common stock of Organicell had expired. Private Placement Of Convertible 6% Debentures As more fully described in Note 9, the Company issued the $150,000 Debentures and $100,000 Debentures that are each subject to conversion (the principal and all accrued but unpaid interest thereon) at the option of the holder at any time, from time to time, commencing 30 trading days after effectiveness of the Company's pending reverse stock split and continuing up to 5 days prior to maturity and (b) at any time during the period following receipt of a Repayment Notice and up to 5 days prior to the date of Prepayment Date, into shares of the common stock of the Company; in the case of the $150,000 Debentures at a conversion price equal to 80% of the VWAP of the common stock of the Company, or in the case of the $100,000 Debentures, at a conversion price of $0.45 per share.

15. Mint Organics

15. Mint Organics	12 Months Ended
	Oct. 31, 2017
Mint Organics
Mint Organics	NOTE 15 – MINT ORGANICS On February 14, 2017, the Company entered into a participation agreement with Mr. Peter Taddeo (“Taddeo”) and Mr. Wayne Rohrbaugh (“Rohrbaugh”), two non-affiliated accredited investors (collectively, the “Investors”) in connection with the Company’s endeavor to obtain a license to dispense medical cannabis in Florida. Pursuant to the agreement, Taddeo and Rohrbaugh each invested $150,000 in the Company and the Company immediately established Mint Organics, Inc. (“Mint Organics”), a 55%-owned subsidiary of the Company and Mint Organics Florida, Inc. (“Mint Organics Florida”), a wholly owned subsidiary of Mint Organics, each dedicated to pursue the objectives of the Agreement (collectively Mint Organics and Mint Organics Florida are referred to as the “Mint Organics Entities”). In connection with the agreement, $150,000 of the proceeds received from the Investors was obligated to be used to fund the operations of the Mint Organics Entities and the remainder was to be used for working capital of the Company. Mint Organics authorized capital consists of (i) 1,000 shares of Class A voting common stock, par value $0.001 per share (“Class A Common Stock”); (ii) 1,000 shares of Class B Non-voting common stock, par value $0.001 per share (“Class B Common Stock”); and (iii) 1,000 shares of Preferred Stock, par value $0.001 per share. Organicell owns 550 shares of Class A Common Stock, representing 100% of the outstanding shares of Class A Common Stock. There are no shares of Class B Common Stock currently outstanding. Pursuant to the Certificate Of Designation filed on February 28, 2017 and as amended on March 23, 2017, Mint Organics authorized 300 shares of Series A convertible preferred stock, par value $0.001 per share and a stated value of $1,000 per share (“Mint Series A Preferred Stock”). The Mint Series A Preferred Stock is non-voting and non-redeemable. The amount of each share of the Mint Series A Preferred Stock shall automatically convert into 1.5 shares of Class B Common Stock of Mint Organics upon the earlier of (a) the fifth anniversary of the date such share of Mint Series A Preferred Stock was issued; or (b) Mint Organics’ receipt of the necessary licenses and permits required to operate business operations in the medical cannabis industry. In addition, commencing on the first anniversary of the issuance date and for the 90-day period thereafter, each holder of the Mint Series A Preferred Stock shall have the right, but not the obligation, to convert some or all of such holder’s shares of Mint Series A Preferred Stock (or Class B Common Stock equivalent) into unregistered shares, par value $0.001 per share, of common stock of Organicell, based on the stated value divided by the average trading price of Organicell common stock for the ten trading days prior the conversion date. Notwithstanding the foregoing, the number of shares of Class B Common Stock issuable upon the conversion of the outstanding Mint Series A Preferred Stock shall be adjusted to ensure that the outstanding Class B Common Stock represents 45% of the outstanding capital stock of Mint Organics (based on conversion of 300 shares of the Mint Series A Preferred Stock or pro rata portion thereof). In connection with the agreement, Mint Organics issued to each of Taddeo and Rohrbaugh (i) 150 shares of Mint Series A Preferred Stock and (ii) a warrant exercisable for up to 150,000 shares of Organicell’s common stock for $0.15 per share exercisable from the date of issuance until the third anniversary of the date of issuance (see Note 13). In addition, in connection with the agreement, Taddeo was appointed as the Chief Executive Officer and as a director of the Mint Organics Entities. Rohrbaugh was appointed as the Chief Operating Officer and as a director of the Mint Organics Entities. On March 8, 2017, Mint Organics issued warrants to purchase shares of Class A Common Stock, of Mint Organics, vesting on the date Mint Organics, through one of its subsidiaries, obtains a license from a state to dispense cannabis until the fifth anniversary thereof to the following executives of Mint Organics: Name: Warrants Exercise Price: Albert Mitrani 79 $ 0.001 Ian T. Bothwell 79 $ 0.001 Dr. Maria I. Mitrani 79 $ 0.001 TOTAL 237 In connection with an independent valuation using a Black-Scholes option model, the fair value of the warrants issued were determined to be $34,949. As described above, the vesting of the warrants are contingent upon the completion of future events. The Company has estimated that the warrants will be fully vested by December 31, 2017. As a result, the Company has recorded amortization expense totaling $27,960 for the period from date the warrants were issued through October 31, 2017 as additional stock-based compensation. Taddeo Employment Agreement Pursuant to an employment agreement entered into effective May 1, 2017, with Mr. Taddeo (“Taddeo”) and Mint Organics (“Taddeo Employment Agreement”), Mr. Taddeo shall serve as the Chief Executive Officer of Mint Organics (“Mint CEO”) and a member of the Board of Directors of Mint Organics (“Mint Board”). The employment term shall be for three years, unless terminated earlier pursuant to the terms of the agreement, and thereafter deemed to be automatically extended, upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term at least 90 days prior to the applicable renewal date. The Mint CEO’s base annual salary is $180,000 during the period prior to Mint Organics, through one of its subsidiaries, or by other means, obtains or acquires access for a license from a state to dispense cannabis which shall accrue commencing as of the effective date and shall be payable upon Mint Organics generating sufficient net revenue or obtaining sufficient third party financing; and thereafter payable in periodic installments in accordance with Mint Organics customary payroll practices, but no less frequently than monthly. The Mint CEO’s base salary shall automatically be adjusted to an annual rate of base salary of $250,000 once the license is obtained. The base salary shall be reviewed at least annually by the Mint Board and the Mint Board may, but shall not be required to, increase the base salary during the employment term. In connection with the execution of the agreement, Mint Organics agreed to pay the Mint CEO a $25,000 signing bonus which shall be accrued and paid by Mint Organics upon Mint Organics having sufficient cash flow. The agreement also contains terms regarding eligibility for future annual bonuses, annual equity awards under Mint Organics’ equity plan, if any, fringe benefits and perquisites consistent with the practices Mint Organics (including health and dental insurance, an automobile expense allowance of $1,000 per month, and reimbursement for all reasonable and necessary out-of-pocket business, entertainment and travel expenses incurred by the Mint CEO in accordance with Mint Organics’ expense reimbursement policies. Mint Organics may terminate the agreement at any time with or without “Cause” and the Mint CEO may resign at any time with or without “Good Reason” (as defined in the agreement). The nature of the obligations owing to the Mint CEO upon termination is more fully described in the agreement. In connection with the execution of the agreement, the Company granted the Mint CEO 1,000,000 shares of unregistered common stock of Organicell, which vested on December 31, 2017 (see Note 12). On April 6, 2018, Peter Taddeo resigned as a member of the Board of Directors of the Company and as the Chief Executive Officer and member of the board of directors of the Mint Organics Entities. In connection with Mr. Taddeo’s resignation, Mr. Taddeo entered into a Separation and General Release Agreement (“Taddeo Separation Agreement”) whereby Mr. Taddeo agreed to release the Mint Organics Entities from all obligations in connection with the Taddeo Agreement and all other agreements and/or financial obligations between the parties related to the Taddeo’s employment or services performed with any of Mint Organics Entities. In consideration for Taddeo entering into the Taddeo Separation Agreement, the Mint Organics Entities paid Taddeo $5,000 and Mr. Bothwell paid $3,000 to Taddeo for the purchase of the 1,000,000 shares of common stock of the Company that were granted to Taddeo in connection with the Taddeo Agreement. Contemporaneously with the execution of the Taddeo Separation Agreement, the Company and Mr. Taddeo entered into a Share Purchase and General Release Agreement whereby the Company agreed to purchase from Mr. Taddeo his 150 shares of Mint Series A Preferred Stock for an aggregate purchase price of $40,000. Mint Organics Florida, Inc. Mint Organics Florida’s authorized capital structure consists of (1) 10,000 shares of Class A voting common stock (“Class A Common Stock”), par value $0.001 per share and (ii) 10,000 shares of Class B Non-voting common stock (“Class B Common Stock”), par value $0.001 per share. The Class A Common Stock shall have the sole right and power to vote on all matters on which a vote of shareholders is to be taken. In all matters, with respect to actions both by vote and by consent, each holder of shares of the Class A Common Stock shall be entitled to cast one vote in person or by proxy for each share of Class A Common Stock standing in such holder’s name on the transfer books of the Corporation. The Class B Common Stock shall not be entitled to vote on any matters. On February 28, 2017, the Board of Mint Organics Florida issued 2,125 shares of Class A Common Stock, par value $0.001 per share, of Mint Organics Florida to Mint Organics and determined that the fair consideration for the initial issuance of the Class A Common Stock is $0.001 per share. Offering: On March 17, 2017, Mint Organics Florida initiated an offering to raise up to $1,000,000 in exchange for up to 212.5 shares of Class B Common Stock, representing approximately 10.0% of the outstanding equity of Mint Organics Florida as of the date of the offering. The proceeds of the offering were to be used for general working capital purposes. On April 6, 2017, Mint Organics received proceeds of $100,000 in connection with the sale of 21.25 units to an investor in connection with the offering (representing a 1% minority interest in the equity of Mint Organics Florida). Agreements: On February 15, 2017, Mint Organics Florida entered into a consulting agreement (“Lobby Consulting Agreement”) with a lobbying firm in connection with Mint Organics Florida’s efforts to obtain a license to dispense medical cannabis in Florida. The initial term of the Lobby Consulting Agreement was for a minimum period of one year and could automatically renew for additional one-year terms unless either party provided 60 days’ prior written notice of intent to cancel the agreement. Under the terms of the Lobby Consulting Agreement, Mint Organics Florida is required to pay a monthly fee of $7,500, plus expenses and upon Mint Organics Florida’s receipt of a license to dispense medical cannabis in Florida, the lobbying firm was entitled to receive a 3% equity interest in Mint Organics Florida through granting of 63.75 shares of Class B Common Stock of Mint Organics Florida. As of October 31, 2017, Mint Organics had not been successful in obtaining the required licenses to operate MMTC’s and had exhausted all of its working capital and therefore was unable to continue efforts towards development of that business. Effective October 31, 2017, Mint Organics Florida and the lobbying firm agreed to mutually terminate the Lobby Consulting Agreement whereby Mint Organics Florida agreed to pay all consulting fees owing under the Lobby Consulting Agreement through October 31, 2017 and issue the lobbying firm the 3% equity interest in Mint Organics Florida Class B Common Stock, regardless of the contingency terms for such issuance provided for in the Lobby Consulting Agreement. As of October 31, 2017, Mint Organics Florida had provided the lobbying firm the agreed upon equity interests and $7,500 of the remaining accrued fees due to the lobbying firm were paid during the quarter ended January 31, 2018. Non-controlling interests in Mint Organics and Mint Organics Florida The Company’s non-controlling interests in Mint Organics and Mint Organics Florida at October 31, 2017 are determined based on the pro rata equity percentage held by the non-controlling equity holders of Mint Organics and Mint Organics Florida of 45.0% and 1.0%, respectively, provided however, that the carrying amount of non-controlling interests shall not be negative. As of October 31, 2017, the non-controlling interests representing the minority interest’s share of Mint Organics and Mint Organics Florida equity was $52,744.

16. Discontinued Operations

16. Discontinued Operations	12 Months Ended
	Oct. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	NOTE 16 – DISCONTINUED OPERATIONS During September 2015, the Company formed Ethan NY for the purpose of selling clothing and accessories through a retail store. During June 2016, the Ethan NY operations were closed and as a result the operations of Ethan NY have been reflected as discontinued operations in the financial statements. The following summarizes the carrying amounts of the assets and liabilities of Ethan NY at October 31, 2017 and 2016: October 31, 2017 2016 Assets: Cash $ – $ – Inventories – – Prepaid Expenses – – Security Deposits – – Property, Plant and Equipment, net – – $ – $ – Liabilities: Accounts Payable $ 94,835 $ 94,835 Accrued Expenses 31,016 31,016 Deferred Rent – – $ 125,851 $ 125,851 The following summaries Ethan NY’s revenues and expenses, net and net income of discontinued operations: Year Ended October 31, 2017 2016 Revenues $ – $ 68,598 Expenses, net – 265,753 Income (Loss) From Discontinued Operations $ – $ (197,155 )

17. Segment Information

17. Segment Information	12 Months Ended
	Oct. 31, 2017
Segment Reporting [Abstract]
Segment Information	NOTE 17 - SEGMENT INFORMATION Beginning during the quarter ended July 31, 2017, the Company had two operating segments (providing of anti-aging and cellular therapy patient marketing and product sales (“Referral and Product Sales”) and the operating of Medical Marijuana Treatment Centers for defined MMTC licensed activities (“MMTC Activities”). The MMTC Activities have not obtained the required licenses to open and operate MMTC’s and to date has not generated revenues. The following are amounts related to the Referral and Product Sales and the MMTC businesses included in the accompanying consolidated financial statements for the year ended October 31, 2017. Because the MMTC Activities did not commence until the year ended October 31, 2017, there are no amounts attributable for that segment during the year ended October 31, 2016: Year Ended October 31, 2017 2016 Revenues: Referrals and product sales $ 569,845 $ 184,881 MMTC Activities – – Total revenues $ 569,845 $ 184,881 Gross profit (loss): Referrals and product sales $ 409,219 $ 90,479 MMTC Activities – – Gross profit (loss) $ 409,219 $ 90,479 Net loss from continuing operations: Referrals and product sales $ (8,662,291 ) $ (1,056,046 ) MMTC Activities (309,841 ) – Net loss from continuing operations $ (8,972,132 ) $ (1,056,046 ) October 31, 2017 October 31, 2016 Total assets: Referrals and product sales $ 375,522 $ 69,898 MMTC Activities 1,258 – Total $ 376,780 $ 69,898

18. Subsequent Events

18. Subsequent Events	12 Months Ended
	Oct. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	NOTE 18 – SUBSEQUENT EVENTS Several subsequent events are disclosed in Notes 1, 4, 5, 8, 9, 12, 13, and 14. There were no other subsequent events for disclosure purposes.

2. Summary of Significant Acc_2

2. Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Oct. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform with the current financial statement presentation including adjusted footnotes to reflect the presentation of discontinued operations as further discussed in Note 16.
Concentrations of Credit Risk	Concentrations of Credit Risk The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $250,000 per institution. At October 31, 2017, the Company did not have any cash balances in financial institutions in excess of FDIC insurance coverage. During the fiscal year ended October 31, 2017, the Company had one customer that accounted for approximately $94,130 of revenues (16.2%) and another customer accounted for approximately $93,000 of revenues (16%). At October 31, 2017, the Company had three customers that accounted for approximately $39,000 (37%), $28,000 (26%) and $18,000 (17%) of accounts receivable, respectively. During the fiscal year ended October 31, 2017, the Company purchased raw materials and other supplies used in manufacturing its products from one supplier totaling approximately $169,000 or 70% of the total amount of materials purchased during the period. The Company’s sales and supply agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products and/or the availability of raw materials and/or products from other suppliers. Since February 2017 (and up through the Sale), the Company manufactured and distributed proprietary products that reduced exposure from reliance on third party suppliers of inventory but increased exposure of reliance on raw materials and other supplies used in the manufacturing of its products.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company's customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. For the year ended October 31, 2017 and 2016, the Company recorded bad debt expense of $5,250 and $500, respectively.
Inventory	Inventory Inventory is stated at the lower of cost or market using the average cost method. The Company regularly reviews inventory quantities on hand to identify slow-moving merchandise and markdowns necessary to clear slow-moving merchandise. Estimates of markdown requirements may differ from actual results due to changes in quantity, quality and mix of products in inventory, as well as changes in consumer preferences, market and economic conditions.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of property and equipment range from 3 to 5 years. Upon sale or retirement, the cost and related accumulated depreciation and amortization are eliminated from their respective accounts, and the resulting gain or loss is included in results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred.
Revenue Recognition	Revenue Recognition The Company recognizes revenue on arrangements in accordance with FASB ASC Topic. 605 “Revenue Recognition”. In all cases, revenue is recognized only when the price is fixed and determinable, persuasive evidence of an arrangement exists, the service is performed and collectability of the resulting receivable is reasonably assured.
Net Income (Loss) Per Common Share	Net Income (Loss) Per Common Share Basic income (loss) per common share is calculated by dividing the Company's net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company's net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. At October 31, 2017, the Company had 158,137,484 common shares issuable upon the exercise of warrants that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the year ended October 31, 2017. At October 31, 2016, the Company had 1,737,484 common shares issuable upon the exercise of warrants that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the year ended October 31, 2016.
Stock-Based Compensation	Stock-Based Compensation All stock-based payments to employees, including grants of employee stock options, are recognized in the financial statements based on their fair values. Stock options and warrants issued to consultants and other non-employees as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can be more clearly determined.
Income Taxes	Income Taxes The Company is required to file a consolidated tax return that includes all of its subsidiaries. Current income taxes are based on the year’s taxable income for federal and state income tax reporting purposes. Deferred income taxes are provided on a liability basis whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax law and rates on the date of enactment. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. For the years ended October 31, 2017 and 2016, the Company has incurred operating losses, and therefore, there were not any income tax expense amounts recorded during that period associated. Since January 1, 2018, the nominal corporate tax rate in the United States of America is a flat 21 percent due to the passage of the "Tax Cuts and Jobs Act" on December 20, 2017 by the US Senate and House of Representatives.
Valuation of Derivatives	Valuation of Derivatives The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date. We analyzed the derivative financial instruments in accordance with ASC 815. The Company utilized Monte Carlo Simulation models that value the derivative liability based on a probability weighted discounted cash flow model. The Company utilized the fair value standard set forth by the Financial Accounting Standards Board, defined as the amount at which the assets (or liability) could be bought (or incurred) or sold (or settled) in a current transaction between willing parties, that is, other than in a forced or liquidation sale. The derivative liabilities result in a reduction of the initial carrying amount (as unamortized discount) of the Convertible Notes. This derivative liability is marked-to-market each quarter with the change in fair value recorded in the income statement. Unamortized discount is amortized to interest expense using the effective interest method over the life of the Convertible Note.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company includes fair value information in the notes to financial statements when the fair value of its financial instruments is different from the book value. When the book value approximates fair value, no additional disclosure is made. The Company follows FASB ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measurements. It defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities and convertible debt. The estimated fair value of cash, accounts payable and accrued liabilities approximate their carrying amounts due to the short-term nature of these instruments. The Company follows the provisions of ASC 820 with respect to its financial instruments. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. The Company’s convertible promissory notes (see Note 9) which are required to be measured at fair value on a recurring basis under of ASC 815 as of October 31, 2017 are all measured at fair value using Level 3 inputs. Level 3 inputs are unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities as of October 31, 2017: Level one Level two Level three The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company’s derivative liability is measured at fair value on a recurring basis. The Company classifies the fair value of the derivative liability under level three. Based on ASC Topic 815 and related guidance, the Company concluded the common stock issuable pursuant to conversion of the convertible promissory notes are required to be accounted for as derivatives as of the issue date due to a reset feature on the exercise price. At the date of issuance common stock derivative liabilities were measured at fair value using either quoted market prices of financial instruments with similar characteristics or other valuation techniques. The Company records the fair value of these derivatives on its balance sheet at fair value with changes in the values of these derivatives reflected in the consolidated statements of operations as “change in fair value of derivative liabilities.” These derivative instruments are not designated as hedging instruments under ASC 815-10 and are disclosed on the balance sheet under Derivative Liabilities. Further, and in accordance with ASC 815, the embedded derivatives are revalued using a Monte Carlo Simulation model at issuance and at each balance sheet date and marked to fair value with the corresponding adjustment as a “gain or loss on change in fair values” in the consolidated statement of operations. As of October 31, 2017, the fair value of the derivative liabilities included on the accompanying consolidated balance sheet was $663,598. During the year ended October 31, 2017, the Company recognized a gain on change in the fair value totaling $95,971. The Company classifies the fair value of these securities under level three of the fair value hierarchy of financial instruments. The following table presents liabilities that are measured and recognized at fair value as of October 31, 2017 on a recurring and non-recurring basis: Description Level 1 Level 2 Level 3 Gains (Losses) Derivatives $ – $ – $ 663,598 $ 95,971 Fair Value at October 31, 2017 $ – $ – $ 663,598 $ 95,971 Changes in the unobservable input values would likely cause material changes in the fair value of the Company’s Level 3 financial instruments.
Subsequent Events	Subsequent Events The Company has evaluated subsequent events that occurred after October 31, 2017 through the financial statement issuance date for subsequent event disclosure consideration.
New Accounting Pronouncements	New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606).” The new guidance provides new criteria for recognizing revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new guidance requires expanded disclosures to provide greater insight into both revenue that has been recognized and revenue that is expected to be recognized in the future from existing contracts. Quantitative and qualitative information will be provided about the significant judgments and changes in those judgments that management made to determine the revenue that is recorded. This accounting standard update, as amended, will be effective for annual reporting periods beginning after December 15, 2017, and interim reporting periods within annual reporting periods beginning after December 15, 2017. The new revenue standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. Early adoption is permitted, but no earlier than fiscal 2017. The Company has assessed the provisions of the guidance and has determined that there is no impact from the adoption of this guidance on its consolidated financial statements. The Company will adopt the provisions of this guidance beginning in the quarter ended January 31, 2018. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The new standard requires management to assess the company’s ability to continue as a going concern. Disclosures are required if there is substantial doubt as to the company’s continuation as a going concern within one year after the issue date of financial statements. The standard provides guidance for making the assessment, including consideration of management’s plans, which may alleviate doubt regarding the Company’s ability to continue as a going concern. ASU 2014-15 is effective for years ending after December 15, 2016. Early adoption is permitted. The Company has adopted this standard for the year ending October 31, 2017, and management has concluded that there is substantial doubt as to the Company’s continuation as a going concern within one year after the issuance date of the financial statements. In February 2016, a pronouncement was issued by the FASB that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is currently evaluating the impact of the new pronouncement on its financial statements. In April 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation” (topic 718). The FASB issued this update to improve the accounting for employee share-based payments and affect all organizations that issue share based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The updated guidance is effective for annual periods beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption of the update is permitted. The Company adopted this guidance in the first quarter of 2017. The adoption of this update had no material effect on the Company’s financial position or results of operations. The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company's results of operations, financial position or cash flow.

2. Summary of Significant Acc_3

2. Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Oct. 31, 2017
Accounting Policies [Abstract]
Schedule of Fair Value Measured on Recurring and Non-Recurring	The following table presents liabilities that are measured and recognized at fair value as of October 31, 2017 on a recurring and non-recurring basis: Description Level 1 Level 2 Level 3 Gains (Losses) Derivatives $ – $ – $ 663,598 $ 95,971 Fair Value at October 31, 2017 $ – $ – $ 663,598 $ 95,971

6. Inventories (Tables)

6. Inventories (Tables)	12 Months Ended
	Oct. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories totaled $119,555 and $9,944 at October 31, 2017 and October 31, 2016, respectively. October 31, 2017 October 31, 2016 Raw materials and supplies $ 17,637 $ 9,944 Finished goods 101,918 – Total inventories $ 119,555 $ 9,944

7. Property and Equipment (Tabl

7. Property and Equipment (Tables)	12 Months Ended
	Oct. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	October 31, 2017 October 31, 2016 Computer equipment $ 4,084 $ 1,724 Manufacturing equipment 69,089 26,313 73,173 28,037 Less: accumulated depreciation and amortization (19,746 ) (431 ) Total property and equipment, net $ 53,427 $ 27,606

10. Derivative Liabilities (Tab

10. Derivative Liabilities (Tables)	12 Months Ended
	Oct. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Liability	The following table summarizes the derivative liability activity for the year ending October 31, 2017: Description Derivative Liabilities Fair value at October 31, 2016 $ – Change due to issuances 759,569 Change in fair value (95,971 ) Fair value at October 31, 2017 $ 663,598
Schedule of Assumptions	The valuation of the embedded derivatives within the convertible note was completed with the following assumptions: Assumptions April 3, 2017 October 31, 2017 Dividend yield 0.00% 0.00% Risk-free rate for term 1.14% 1.49% Volatility 255.2% 255.3% Remaining Term (years) 1.0 1.50 Stock Price $ 0.0159 $ 0.0084

11. Income Taxes (Tables)

11. Income Taxes (Tables)	12 Months Ended
	Oct. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the U.S. federal statutory tax amount to the Company’s effective tax amount is as follows: Year Ended October 31, 2017 Year Ended October 31, 2016 Income tax benefit at statutory rate (34%) $ (3,098,256 ) $ (426,088 ) Stock-based compensation 1,975,704 – Derivative liabilities & other 135,334 – Change in valuation allowance 987,218 426,088 Total $ – $ –
Schedule of Deferred Tax Assets and Liabilities	The tax effects of temporary differences and carry-forwards that give rise to deferred tax assets and liabilities for the Company were as follows: October 31, October 31, 2017 2016 Deferred tax asset attributable to: Net operating loss carry-forward $ 1,614,725 $ 627,507 Less valuation allowance (1,614,725 ) (627,507 ) Total $ – $ –

13. Warrants (Tables)

13. Warrants (Tables)	12 Months Ended
	Oct. 31, 2017
Warrants
Schedule of Warrants Granted to Purchase Shares of Common Stock	On March 8, 2017, the Board of the Company granted warrants to purchase shares of common stock of the Company on a cashless basis to the following executive officers and directors of the Company: Executive Officer Warrants: Dr. Bruce Werber (Chief Operating Officer and Director) 21,500,000 Ian T. Bothwell (Chief Financial Officer and Director) 21,500,000 Dr. Maria Ines Mitrani (Chief Science Officer and Director) 13,850,000 TOTAL 56,850,000
Summary of Warrant Activity	A summary of warrant activity for the years ended October 31, 2016 and 2017 are presented below. Number of Shares Weighted-average Exercise Price Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at October 31, 2015 1,008,114 $ 0.75 3.78 $ – Granted 729,370 $ 0.75 4.00 $ – Exercised – $ – – – Expired/Forfeited – $ – – – Outstanding and exercisable at October 31, 2016 1,737,484 $ 0.75 3.01 $ – Number of Shares Weighted-average Exercise Price Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at October 31, 2016 1,737,484 $ 0.75 3.01 $ – Granted 156,400,000 $ 0.05 9.90 $ – Exercised – $ – – – Expired/Forfeited – $ – – – Outstanding at October 31, 2017 158,137,484 $ 0.05 9.02 $ – Exercisable at October 31, 2017 155,487,484 $ 0.05 9.02 $ –

14. Commitments and Contingen_2

14. Commitments and Contingencies (Tables)	12 Months Ended
	Oct. 31, 2017
Ethan NY [Member]
Schedule of Lease Payments	The lease payments pursuant to the Ethan Lease were as follows: Year Ended Minimum October 31, Rent 2016 $ 104,785 2017 117,714 2018 121,245 2019 124,882 2020 117,616 2021 – Total $ 586,242
Anu Life Sciences Inc [Member]
Schedule of Lease Payments	The minimum lease payments pursuant to Lab Lease are as follows: Year Ended Minimum October 31, Rent 2018 $ 95,421 2019 99,663 2020 109,049 2021 111,782 2022 75,758 Total $ 491,673

15. Mint Organics (Tables)

15. Mint Organics (Tables)	12 Months Ended
	Oct. 31, 2017
Mint Organics
Schedule of Warrants Issued to Purchase Common Stock for Executives	On March 8, 2017, Mint Organics issued warrants to purchase shares of Class A Common Stock, of Mint Organics, vesting on the date Mint Organics, through one of its subsidiaries, obtains a license from a state to dispense cannabis until the fifth anniversary thereof to the following executives of Mint Organics: Name: Warrants Exercise Price: Albert Mitrani 79 $ 0.001 Ian T. Bothwell 79 $ 0.001 Dr. Maria I. Mitrani 79 $ 0.001 TOTAL 237

16. Discontinued Operations (Ta

16. Discontinued Operations (Tables)	12 Months Ended
	Oct. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet and Additional Disclosures	The following summarizes the carrying amounts of the assets and liabilities of Ethan NY at October 31, 2017 and 2016: October 31, 2017 2016 Assets: Cash $ – $ – Inventories – – Prepaid Expenses – – Security Deposits – – Property, Plant and Equipment, net – – $ – $ – Liabilities: Accounts Payable $ 94,835 $ 94,835 Accrued Expenses 31,016 31,016 Deferred Rent – – $ 125,851 $ 125,851 The following summaries Ethan NY’s revenues and expenses, net and net income of discontinued operations: Year Ended October 31, 2017 2016 Revenues $ – $ 68,598 Expenses, net – 265,753 Income (Loss) From Discontinued Operations $ – $ (197,155 )

17. Segment Information (Tables

17. Segment Information (Tables)	12 Months Ended
	Oct. 31, 2017
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The following are amounts related to the Referral and Product Sales and the MMTC businesses included in the accompanying consolidated financial statements for the year ended October 31, 2017. Because the MMTC Activities did not commence until the year ended October 31, 2017, there are no amounts attributable for that segment during the year ended October 31, 2016: Year Ended October 31, 2017 2016 Revenues: Referrals and product sales $ 569,845 $ 184,881 MMTC Activities – – Total revenues $ 569,845 $ 184,881 Gross profit (loss): Referrals and product sales $ 409,219 $ 90,479 MMTC Activities – – Gross profit (loss) $ 409,219 $ 90,479 Net loss from continuing operations: Referrals and product sales $ (8,662,291 ) $ (1,056,046 ) MMTC Activities (309,841 ) – Net loss from continuing operations $ (8,972,132 ) $ (1,056,046 ) October 31, 2017 October 31, 2016 Total assets: Referrals and product sales $ 375,522 $ 69,898 MMTC Activities 1,258 – Total $ 376,780 $ 69,898

1. Organization and Descripti_2

1. Organization and Description of Business (Details Narrative) - USD ($)	Apr. 23, 2018	May 29, 2015	Oct. 31, 2017	Oct. 30, 2015
John Goodhew [Member]
Number of common stock shares purchased during the period		135,000,000
John Goodhew [Member] | Stock Purchase Agreement [Member]
Purchase price per share				$ 10
Management and Business Associates, LLC [Member]
Number of common stock shares purchased during the period	222,425,073
Stock purchased during the period, value	$ 222,425
Purchase price per share	$ 0.001
Percentage of owned subsidiary	51.00%
Mint Organics Inc [Member] | February 2017 [Member]
Percentage of owned subsidiary			55.00%
Vera Acquisition LLC [Member]
Sale of tangible and other assets	$ 950,000

2. Summary of Significant Acc_4

2. Summary of Significant Accounting Policies (Details - Liabilities recognized at fair value) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
Fair Value at end	$ 663,598	$ 0
Gains (Losses) on derivatives	95,971	$ 0
Gains (Losses) on fair value of derivatives	95,971
Fair Value, Inputs, Level 1 [Member]
Derivatives	0
Fair Value at end	0
Fair Value, Inputs, Level 2 [Member]
Derivatives	0
Fair Value at end	0
Fair Value, Inputs, Level 3 [Member]
Derivatives	663,598
Fair Value at end	$ 663,598

2. Summary of Significant Acc_5

2. Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
FDIC limits per institutions	$ 250,000
Revenue	569,845	$ 184,881
Accounts receivable	107,295	1,125
Cost of revenues	160,626	94,402
Bad debt expense	$ 5,250	500
Corporate tax rate	21.00%
Fair value of derivative liabilities	$ 663,598	0
Change in fair value of derivative liabilities	$ 95,971	$ 0
Minimum [Member]
Property and equipment estimated useful lives	3 years
Maximum [Member]
Property and equipment estimated useful lives	5 years
One Supplier [Member]
Concentration credit risk percentage	70.00%
Cost of revenues	$ 169,000
Sales Revenue, Net [Member] | One Customer [Member]
Revenue	$ 94,130
Concentration credit risk percentage	16.20%
Sales Revenue, Net [Member] | Second Customer [Member]
Revenue	$ 93,000
Concentration credit risk percentage	16.00%
Accounts Receivable [Member] | One Customer [Member]
Accounts receivable	$ 39,000
Concentration credit risk percentage	37.00%
Accounts Receivable [Member] | Second Customer [Member]
Accounts receivable	$ 28,000
Concentration credit risk percentage	26.00%
Accounts Receivable [Member] | Third Customer [Member]
Accounts receivable	$ 18,000
Concentration credit risk percentage	17.00%
Common Shares Issuable Upon Exercise of Warrants [Member]
Antidilutive securities excluded from computation of earnings per share	158,137,484	1,737,484

3. Going Concern (Details Narra

3. Going Concern (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 9,112,519	$ 1,253,201
Accumulated deficit	11,085,743	$ 2,113,611
Working capital deficit	$ (3,599,915)

4. Sale and Transfer of Anu M_2

4. Sale and Transfer of Anu Manufacturing Assets (Details Narrative) - USD ($)	Feb. 05, 2018	Oct. 31, 2017
Warrants forfeited		77,150,000
Issuance of common stock		7,500,000
Fair value stock issued		$ 82,500
Securities Purchase Agreement [Member]
Proceeds from sale of Notes outstanding	$ 762,477
Face value of Notes outstanding	527,778
Accrued and unpaid interest	8,589
Prepayment penalties	211,111
Reimbursement of legal fees	15,000
Vera Acquisition LLC [Member] | Organicell Distribution Agreement [Member]
Cash payment for purchase of assets	950,000
Prepaid of product supply	$ 100,000

5. Reorganization Plan (Details

5. Reorganization Plan (Details Narrative)	12 Months Ended
	Oct. 31, 2017USD ($)$ / sharesshares
Ian T. Bothwell [Member]
Warrants Exercised	48,624,561
Exercise Price | $ / shares	$ 0.001
Common stock granted	4,675,439
Dr. Maria Ines Mitrani [Member]
Warrants Exercised	21,757,895
Exercise Price | $ / shares	$ 0.001
Common stock granted	2,092,105
Reorganization Plan [Member] | Management and Business Associates, LLC [Member]
Stock issued during period, shares, new issues	222,425,073
Stock issued during period, value, new issues | $	$ 222,425

6. Inventories (Details)

6. Inventories (Details) - USD ($)	Oct. 31, 2017	Oct. 31, 2016
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 17,637	$ 9,944
Finished goods	101,918	0
Total Inventories	$ 119,555	$ 9,944

6. Inventories (Details Narrati

6. Inventories (Details Narrative) - USD ($)	Oct. 31, 2017	Oct. 31, 2016
Inventory Disclosure [Abstract]
Inventories	$ 119,555	$ 9,944

7. Property and Equipment (Deta

7. Property and Equipment (Details) - USD ($)	Oct. 31, 2017	Oct. 31, 2016
Property and equipment, gross	$ 73,173	$ 28,037
Less: accumulated depreciation and amortization	(19,746)	(431)
Total property and equipment, net	53,427	27,606
Computer Equipment [Member]
Property and equipment, gross	4,084	1,724
Manufacturing Equipment [Member]
Property and equipment, gross	$ 69,089	$ 26,313

7. Property and Equipment (De_2

7. Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 19,315	$ 345

8. Related Party Transactions (

8. Related Party Transactions (Details Narrative) - USD ($)	May 17, 2017	Mar. 29, 2017	Feb. 28, 2017	Jan. 31, 2017	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2016	Mar. 08, 2017	Nov. 02, 2016
Warrants forfeited						77,150,000
Lease term						24 months
Monthly rent expense						$ 2,800
Security deposit						$ 42,275	$ 5,000
Preferred stock, shares issued						0	0
Preferred stock par value						$ 0.001	$ 0.001
Warrant to purchase shares of common stock						729,370	1,008,114
Warrant exercise price per share			$ 0.15					$ 0.02
Number of sold shares of common stock				100,000
Cost of sale related parties						$ 67,550
Participation Agreement [Member]
Warrant exercise price per share								$ 0.15
Taddeo [Member] | Taddeo Agreement [Member]
Number of sold shares of common stock	1,000,000
Related Party [Member]
Number of sold shares of common stock			250,000
Series A Preferred Stock [Member]
Preferred stock, shares issued						400	400
Preferred stock par value						$ 0.001	$ 0.001
Series A Non-Convertible Preferred Stock [Member]
Preferred stock, shares issued									100
Preferred stock voting percentage						The outstanding shares of Series A Non-Convertible Preferred Stock shall vote together with the shares of common Stock and other voting securities of the Company as a single class and, regardless of the number of shares of Series A Non-Convertible Preferred Stock outstanding, and as long as at least one share of Series A Non-Convertible Preferred Stock is outstanding, such shares shall represent (80%) of all votes entitled to be voted at any annual or special meeting of stockholders of the Company or action by written consent of stockholders. Each outstanding share of the Series A Non-Convertible Preferred Stock shall represent its proportionate share of the 80% which is allocated to the outstanding shares of Series A Non-Convertible Preferred Stock.
Series A Non-Convertible Preferred Stock [Member] | Chief Operating Officer [Member]
Preferred stock, shares issued								100
Series A Non-Convertible Preferred Stock [Member] | Chief Science Officer [Member]
Preferred stock, shares issued								100
Series A Non-Convertible Preferred Stock [Member] | CFO [Member]
Preferred stock, shares issued								100
Series A Non-Convertible Preferred Stock [Member] | Chief Executive Officer [Member]
Preferred stock, shares issued									100
Preferred stock par value									$ 0.001
Chief Executive Officer [Member]
Salary expense							$ 241,845
Paid salary							91,845
Salary and consulting fees							138,729
Paid salary and consulting fees							33,896
Health benefit costs and automobile related allowances							46,868
Reimbursed expenses							44,000
Accrued salary related expense							150,000
Due to related party							150,000
Warrant exercise price per share								$ 0.001
Chief Executive Officer [Member] | Series A Preferred Stock [Member]
Preferred stock, shares issued									100
Preferred stock par value									$ 0.001
Chief Science Officer [Member]
Accrued salary related expense							104,833
Due to related party							$ 104,833
Warrants forfeited					23,850,000
Common stock received from exercise of warrants					2,092,105
Common stock granted					2,092,105
Value of shares granted					$ 33,474
Warrant exercise price per share								$ 0.001
Chief Science Officer [Member] | Series A Preferred Stock [Member]
Preferred stock, shares issued								100
Chief Financial Officer [Member]
Warrants forfeited					53,300,000
Common stock received from exercise of warrants					4,675,439
Common stock granted					4,675,439
Value of shares granted					$ 74,807
Number of common shares granted		1,000,000
Warrant exercise price per share								$ 0.001
Chief Financial Officer [Member] | Series A Preferred Stock [Member]
Preferred stock, shares issued								100
Chief Operating Officer [Member]
Warrants forfeited						53,300,000
Common stock received from exercise of warrants						4,675,439
Number of common shares granted		1,000,000
Number of sold shares of common stock			250,000
Chief Operating Officer [Member] | Series A Preferred Stock [Member]
Preferred stock, shares issued								100
Mr. Peter Taddeo [Member]
Preferred stock, shares issued			150
Warrant exercise price per share			$ 0.15
Mr. Wayne Rohrbaugh [Member]
Preferred stock, shares issued			150
Warrant exercise price per share			$ 0.15
Maximum [Member]
Monthly rent expense						$ 2,500
March 29, 2017 [Member] | Chief Financial Officer [Member]
Due to officer						150,000
Converted amount of advances and unreimbursed expenses						$ 300,000
Number of common shares granted						1,000,000
Number of common shares granted, value						$ 31,840
March 29, 2017 [Member] | Chief Operating Officer [Member]
Due to officer						150,000
Converted amount of advances and unreimbursed expenses						$ 300,000
Number of common shares granted						1,000,000
Number of common shares granted, value						$ 31,840
February 14, 2017 [Member] | Preferred Stock [Member] | Participation Agreement [Member]
Preferred stock par value						$ 0.001
February 14, 2017 [Member] | Mr. Peter Taddeo [Member]
Preferred stock, shares issued						150
Warrant to purchase shares of common stock						150,000
Warrant exercise price per share						$ 0.15
Invested amount						$ 150,000
February 14, 2017 [Member] | Mr. Wayne Rohrbaugh [Member]
Preferred stock, shares issued						150
Warrant to purchase shares of common stock						150,000
Warrant exercise price per share						$ 0.15
Invested amount						$ 150,000
February 2017 [Member] | Chief Operating Officer [Member]
Number of sold shares of common stock						250,000
Aggregate purchase price						$ 10,000
March17, 2017 [Member] | Taddeo [Member] | Taddeo Agreement [Member]
Number of sold shares of common stock						1,000,000
Sale of stock price per share						$ 0.012
March 8, 2017 [Member]
Warrant exercise price per share						$ 0.02
March 8, 2017 [Member] | Participation Agreement [Member]
Warrant to purchase shares of common stock						150,000
Warrant exercise price per share						$ 0.15
March 8, 2017 [Member] | Series A Preferred Stock [Member]
Preferred stock voting percentage						The Series A Preferred Stock shall vote together with the shares of common stock and other voting securities of the Company as a single class and such shares shall represent 80% of all votes entitled to be voted at any annual or special meeting of stockholders of the Company or action by written consent of stockholders.
March 8, 2017 [Member] | Chief Executive Officer [Member]
Warrant to purchase shares of common stock						79
Warrant exercise price per share						$ 0.001
March 8, 2017 [Member] | Chief Science Officer [Member]
Warrant to purchase shares of common stock						79
Warrant exercise price per share						$ 0.001
March 8, 2017 [Member] | Chief Financial Officer [Member]
Warrant to purchase shares of common stock						79
Warrant exercise price per share						$ 0.001
NovemberOneTwoThousandSixteenMember | Series A Non-Convertible Preferred Stock [Member]
Preferred stock, shares issued						100
Preferred stock par value						$ 0.001
NovemberOneTwoThousandSixteenMember | Series A Non-Convertible Preferred Stock [Member] | Chief Executive Officer [Member]
Preferred stock, shares issued						100
Preferred stock par value						$ 0.001
MarchEightTwoThousandSeventeenMember | Series A Non-Convertible Preferred Stock [Member] | Chief Operating Officer [Member]
Preferred stock, shares issued						100
MarchEightTwoThousandSeventeenMember | Series A Non-Convertible Preferred Stock [Member] | Chief Science Officer [Member]
Preferred stock, shares issued						100
MarchEightTwoThousandSeventeenMember | Series A Non-Convertible Preferred Stock [Member] | CFO [Member]
Preferred stock, shares issued						100
FebruaryTwoThousandSeventeenMember | Related Party [Member]
Number of sold shares of common stock						250,000
Sale of stock price per share						$ 0.04
February 5, 2018 [Member] | Chief Executive Officer [Member] | Series A Preferred Stock [Member]
Preferred stock, shares Forfeited						100
February 5, 2018 [Member] | Chief Science Officer [Member] | Series A Preferred Stock [Member]
Preferred stock, shares Forfeited						100
February 5, 2018 [Member] | Chief Financial Officer [Member] | Series A Preferred Stock [Member]
Preferred stock, shares Forfeited						100
February 5, 2018 [Member] | Chief Operating Officer [Member] | Series A Preferred Stock [Member]
Preferred stock, shares Forfeited						100

9. Notes Payable (Details Narra

9. Notes Payable (Details Narrative)	Aug. 10, 2018USD ($)Days$ / shares	Feb. 05, 2018USD ($)	Apr. 27, 2016USD ($)	Dec. 24, 2015USD ($)	Nov. 12, 2015USD ($)	Jun. 20, 2018USD ($)Days	Oct. 31, 2018USD ($)	Oct. 31, 2017USD ($)Days$ / sharesshares	Oct. 31, 2016USD ($)	Sep. 19, 2017shares	Jun. 22, 2017USD ($)
Interest expense								$ 348,249	$ 0
Interest payments								47,108
Stock issued during period, value, new issues								82,500
Accredited Investors [Member]
Debt trading days | Days	30					30
Debt conversion price per share | $ / shares	$ 0.45
Unamortized discount	$ 100,000					$ 150,000
Interest rate	6.00%					6.00%
Debenture issued	$ 100,000					$ 150,000
Payment for general working capital purposes	$ 100,000					$ 150,000
Third Tranche [Member]
Payment of note payable							$ 35,000
Second Tranche [Member]
Payment of note payable							50,000
Initial Tranche [Member]
Payment of note payable							$ 15,000
Unsecured Loan Agreement [Member]
Debt principal amount			$ 35,000	$ 50,000	$ 15,000
Proceeds from issuance of debt			35,000	50,000	15,000
Note payable			$ 42,000	$ 50,000	$ 15,000
Debt interest percentage			221.00%	8.00%	8.00%
Debt term				1 year	1 year
Debt due date			May 31, 2016
Unsecured Loan Agreement [Member] | Mint Organics Inc [Member]
Interest expense								2,170
Unsecured loan principal balance											$ 60,000
Interest rate											10.00%
Securities Purchase Agreement One [Member] | April 3, 2017 [Member]
Payment of note payable								50,000
Securities Purchase Agreement [Member]
Debt principal amount								333,333
Debt subscription amount								300,000
Remaining amount of debt								$ 175,000
Participate tranche description								In the event that any Purchaser does not participate in any Tranche after the second Tranche, the remaining Purchasers shall have the right to participate in such Tranche in an amount up to 100% of the entire Tranche. In the event that such participating Purchasers do not collectively fund 100% of the desired Tranche amount, then the Company shall be permitted to request from any Person (as defined in the SPA) the remaining amount, so long as such Person(s) agree to execute the SPA (and further, the Company and the Purchasers agree to amend the Agreement and the Note as necessary). The Company is not obligated to consummate any additional Tranche fundings subsequent to the second Tranche.
Initial carrying amount of note								$ 0
Original issue discount								116,458
Derivative liabilities								759,569
Unamortized discount								411,320
Excess amount carrying value								348,249
Gain on derivative liabilities								$ 95,971
Proceeds from sale of Notes outstanding		$ 762,477
Face value of Notes outstanding		527,778
Accrued and unpaid interest		8,589
Prepayment penalties		211,111
Reimbursement of legal fees		$ 15,000
Securities Purchase Agreement [Member] | Ian T. Bothwell [Member]
Stock issued during period, shares, new issues | shares								1,000,000
Stock issued during period, value, new issues								$ 63,580
Securities Purchase Agreement [Member] | Agent [Member]
Stock issued during period, shares, new issues | shares								2,000,000
Stock issued during period, value, new issues								$ 63,580
Securities Purchase Agreement [Member] | Werber [Member]
Stock issued during period, shares, new issues | shares								1,000,000
Stock issued during period, value, new issues								$ 63,580
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member]
Debt principal amount								$ 1,666,667
Debt interest percentage								10.00%
Debt due date								Mar. 31, 2018
Percentage of original issue of discount								10.00%
Debt subscription amount								$ 1,500,000
Debt description								The unpaid principal amount of the Note shall accrue interest at 10% per annum, provided that upon the occurrence and during the continuance of an event of default as defined in the SPA, the outstanding principal amount of this Note and any accrued and unpaid interest and all other overdue amounts shall each bear interest until paid at the rate of 18% per annum. Additionally, in the event that the publicly traded price of the common stock falls below $0.0125 for 3 consecutive trading days, then the Note shall accrue interest at the default interest rate. During the period April 27, 2017 to May 1, 2017, the closing price of the common stock fell below $0.0125 and accordingly beginning May 2, 2017, the default interest rate of 18% is in effect.
Debt default interest rate								18.00%
Debt stock price per share | $ / shares								$ 0.0125
Debt trading days | Days								3
Interest expense								$ 366,857
Common stock reversed | shares										82,008,230
Debt conversion price per share | $ / shares								$ 0.15
Debt conversion price percentage								60.00%
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member] | Minimum [Member]
Prepayment penalty percentage								20.00%
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member] | Maximum [Member]
Prepayment penalty percentage								40.00%
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member] | Purchasers [Member]
Debt principal amount								$ 666,667
Debt subscription amount								600,000
Securities Purchase Agreement [Member] | April 3, 2017 [Member]
Payment of note payable								$ 15,000
Securities Purchase Agreement [Member] | April 27, 2017 to May 1, 2017 [Member]
Debt default interest rate								18.00%
Debt stock price per share | $ / shares								$ 0.0125
Securities Purchase Agreement [Member] | Second Tranche [Member] | Convertible Promissory Note [Member]
Debt principal amount								$ 138,889
Debt subscription amount								125,000
Securities Purchase Agreement [Member] | Initial Tranche [Member] | Convertible Promissory Note [Member]
Debt principal amount								527,778
Debt subscription amount								475,000
Securities Purchase Agreement Two [Member] | April 3, 2017 [Member]
Payment of note payable								$ 35,000

10. Derivative Liabilities (Det

10. Derivative Liabilities (Details - Derivative Liability Activity) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair value, beginning	$ 0
Change due to issuances	759,569
Change in fair value of derivative liabilities	(95,971)	$ 0
Fair value, ending	$ 663,598	$ 0

10. Derivatives (Details - Assu

10. Derivatives (Details - Assumptions) - Embedded Derivative Financial Instruments [Member]	12 Months Ended
	Oct. 31, 2017	Oct. 30, 2017	Oct. 31, 2016	Oct. 30, 2016
Measurement Input, Expected Dividend Rate [Member]
Assumptions	0.00%		0.00%
Measurement Input Risk Free Interest Rate [Member]
Assumptions	1.14%		1.49%
Measurement Input, Option Volatility [Member]
Assumptions	255.20%		255.30%
Measurement Input, Expected Term [Member]
Assumptions		1year		1.5years
Measurement Input, Share Price [Member]
Assumptions	0.0159		0.0084

10. Derivative Liabilities (D_2

10. Derivative Liabilities (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Change in fair value of derivative liabilities	$ 95,971	$ 0

11. Income Taxes (Details - Eff

11. Income Taxes (Details - Effective Reconciliation of Income Tax) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
Income Tax Disclosure [Abstract]
Income tax benefit at statutory rate (34%)	$ (3,098,256)	$ (426,088)
Stock-based compensation	1,975,704	0
Derivative liabilities & other	135,334	0
Valuation allowance	987,218	426,088
Total	$ 0	$ 0

11. Income Taxes (Details - Def

11. Income Taxes (Details - Deferred Tax Assets) - USD ($)	Oct. 31, 2017	Oct. 31, 2016
Deferred tax asset attributable to:
Net operating loss carry-forward	$ 1,614,725	$ 627,507
Less valuation allowance	(1,614,725)	(627,507)
Total	$ 0	$ 0

11. Income Taxes (Details Narra

11. Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
Income Tax Disclosure [Abstract]
Statutory income tax rate	34.00%	34.00%
Net operating loss carryforward	$ 4,749,000
Operating loss expiration	will expire beginning in 2031
Valuation of allowance percentage	100.00%
Penalties	$ 90,000
Accrued tax penalties	$ 90,000

12. Capital Stock (Details Narr

12. Capital Stock (Details Narrative) - USD ($)	May 17, 2017	Mar. 29, 2017	Aug. 31, 2016	Sep. 17, 2015	Apr. 30, 2018	Mar. 31, 2018	Feb. 28, 2018	Jan. 31, 2018	Feb. 28, 2017	Jan. 31, 2017	Sep. 30, 2016	Jul. 31, 2016	Apr. 30, 2016	Mar. 31, 2016	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2016	Apr. 23, 2018	Mar. 08, 2017	Nov. 02, 2016
Preferred stock, shares authorized																10,000,000	10,000,000
Preferred stock, par value																$ 0.001	$ 0.001
Preferred stock, shares issued																0	0
Common stock, shares authorized																750,000,000	750,000,000
Common stock, par value																$ 0.001	$ 0.001
Forward stock split				eighteen-for-one forward stock split
Number of common stock shares sold during the period										100,000
Proceeds from issuance of common stock									$ 30,000	$ 60,000						$ 400,000
Warrants to purchase share of common stock																729,370	1,008,114
Exercise price of warrants									$ 0.15										$ 0.02
Fair value of warrants issued																$ 379,893
Warrants forfeited																77,150,000
Issuance of common stock																7,500,000
Chief Operating Officer [Member]
Number of common stock shares sold during the period									250,000
Stock-based compensation expense																$ 82,500
Warrants forfeited																53,300,000
Issuance of common stock																7,500,000
Common stock received from exercise of warrants																4,675,439
Chief Technology Officer [Member]
Stock-based compensation expense																$ 82,500
Warrants forfeited																23,850,000
Issuance of common stock																7,500,000
Common stock received from exercise of warrants																2,092,105
Chief Financial Officer [Member]
Exercise price of warrants																			0.001
Stock-based compensation expense															$ 74,807
Warrants forfeited															53,300,000
Common stock received from exercise of warrants															4,675,439
Common stock granted															4,675,439
Chief Science Officer [Member]
Exercise price of warrants																			$ 0.001
Stock-based compensation expense															$ 33,474
Warrants forfeited															23,850,000
Common stock received from exercise of warrants															2,092,105
Common stock granted															2,092,105
Maximum [Member]
Common stock, shares authorized																250,000,000
Common stock, par value																$ 0.001
Management and Business Associates, LLC [Member]
Sale of stock, price per share																		$ 0.001
Management and Business Associates, LLC [Member] | Reorganization Plan [Member]
Issuance of common stock																222,425,073
Stock issued during period, value, new issues																$ 222,425
Common Stock [Member]
Proceeds from issuance of common stock
Stock issued during period, value, new issues																$ 2,150	$ 5,017
9 Accredited Investors [Member]
Number of common stock shares sold during the period														364,685
Proceeds from issuance of common stock														$ 255,279
9 Accredited Investors [Member] | Common Stock [Member]
Number of common stock shares sold during the period														729,370
Warrant term														4 years
Fair value of warrants issued														$ 379,893
Individual [Member]
Number of common stock shares sold during the period													25,000
Proceeds from issuance of common stock													$ 5,000
Investors [Member]
Number of common stock shares sold during the period												2,200,000
Proceeds from issuance of common stock												$ 92,000
Investors [Member] | One Class A Warrant [Member]
Warrants to purchase share of common stock																	192,857
Exercise price of warrants																	$ 0.50
Investors [Member] | One Class B Warrant [Member]
Warrants to purchase share of common stock																	192,857
Exercise price of warrants																	$ 1
Accredited Investors [Member]
Number of common stock shares sold during the period			62,500		625,000	313,500	1,250,000	4,062,500		100,000	2,000,000
Proceeds from issuance of common stock			$ 5,000		$ 10,000	$ 5,000	$ 20,000	$ 65,000		$ 5,000	$ 100,000
Related Party [Member]
Number of common stock shares sold during the period									250,000
Bothwell [Member] | Securities Purchase Agreement [Member]
Number of common stock shares sold during the period		1,000,000
Werber [Member] | Securities Purchase Agreement [Member]
Number of common stock shares sold during the period		1,000,000
Agent [Member] | Securities Purchase Agreement [Member]
Number of common stock shares sold during the period		2,000,000
Taddeo [Member] | Taddeo Agreement [Member]
Number of common stock shares sold during the period	1,000,000
Series A Non-Convertible Preferred Stock [Member]
Preferred stock, shares authorized																				10,000,000
Preferred stock, shares issued																				100
Preferred stock voting rights																The outstanding shares of Series A Non-Convertible Preferred Stock shall vote together with the shares of common Stock and other voting securities of the Company as a single class and, regardless of the number of shares of Series A Non-Convertible Preferred Stock outstanding, and as long as at least one share of Series A Non-Convertible Preferred Stock is outstanding, such shares shall represent (80%) of all votes entitled to be voted at any annual or special meeting of stockholders of the Company or action by written consent of stockholders. Each outstanding share of the Series A Non-Convertible Preferred Stock shall represent its proportionate share of the 80% which is allocated to the outstanding shares of Series A Non-Convertible Preferred Stock.
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized																				10,000,000
Series A Preferred Stock [Member]
Preferred stock, shares authorized																400	400
Preferred stock, par value																$ 0.001	$ 0.001
Preferred stock, shares issued																400	400
Series A Preferred Stock [Member] | Chief Operating Officer [Member]
Preferred stock, shares issued																			100
Series A Preferred Stock [Member] | Chief Financial Officer [Member]
Preferred stock, shares issued																			100
Series A Preferred Stock [Member] | Chief Science Officer [Member]
Preferred stock, shares issued																			100
NovemberOneTwoThousandSixteenMember | Series A Non-Convertible Preferred Stock [Member]
Preferred stock, shares authorized																10,000,000
Preferred stock, par value																$ 0.001
Preferred stock, shares issued																100
NovemberOneTwoThousandSixteenMember | Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized																10,000,000
Preferred stock, shares designated																1,000,000
June 6, 2017 [Member] | Maximum [Member]
Common stock, shares authorized																750,000,000
June 6, 2017 [Member] | Minimum [Member]
Common stock, shares authorized																250,000,000
June 6, 2017 [Member] | Series A Preferred Stock [Member]
Percentage of voting equivalency of outstanding capital stock																80.00%
January 2017 to February 2017 [Member]
Number of common stock shares sold during the period																90,000
Proceeds from issuance of common stock																$ 90,000
Warrant term																3 years
Fair value of warrants issued																$ 33,480
January 2017 to February 2017 [Member] | One Class A Warrant [Member]
Warrants to purchase share of common stock																900,000
Exercise price of warrants																$ 0.075
January 2017 to February 2017 [Member] | One Class B Warrant [Member]
Warrants to purchase share of common stock																900,000
Exercise price of warrants																$ 0.150
FebruaryTwoThousandSeventeenMember | Related Party [Member]
Number of common stock shares sold during the period																250,000
Proceeds from issuance of common stock																$ 10,000
Sale of stock, price per share																$ 0.04
MarchEightTwoThousandSeventeenMember | Parent Company [Member] | Mint Organics Inc [Member] | Consulting Services [Member]
Stock-based compensation expense																$ 3,000
Issuance of shares of unregistered common stock																100,000
MarchTwentyNineTwoThousandSeventeenMember | Bothwell [Member] | Securities Purchase Agreement [Member]
Number of common stock shares sold during the period																1,000,000
Proceeds from issuance of common stock																$ 63,680
MarchTwentyNineTwoThousandSeventeenMember | Werber [Member] | Securities Purchase Agreement [Member]
Number of common stock shares sold during the period																1,000,000
Proceeds from issuance of common stock																$ 63,680
MarchTwentyNineTwoThousandSeventeenMember | Agent [Member] | Securities Purchase Agreement [Member]
Number of common stock shares sold during the period																2,000,000
Proceeds from issuance of common stock																$ 63,680
March17, 2017 [Member] | Taddeo [Member] | Taddeo Agreement [Member]
Number of common stock shares sold during the period																1,000,000
Proceeds from issuance of common stock																$ 12,000
Sale of stock, price per share																$ 0.012
Stock-based compensation expense																$ 8,800

13. Warrants (Details - Warrant

13. Warrants (Details - Warrants Granted to Purchase Shares of Common Stock)	Oct. 31, 2017shares
Total	56,850,000
Dr. Bruce Werber [Member]
Total	21,500,000
Ian T. Bothwell [Member]
Total	21,500,000
Dr. Maria Ines Mitrani [Member]
Total	13,850,000

13. Warrants (Details - Warra_2

13. Warrants (Details - Warrant Activity) - Warrant [Member] - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
Number of Shares Outstanding beginning balance	1,737,484	1,008,114
Number of Shares, Granted	156,400,000	729,370
Number of Shares, Exercised	0	0
Number of Shares, Expired/Forfeited	0	0
Number of Shares Outstanding ending balance	158,137,484	1,737,484
Number of shares Exercisable	155,487,484
Weighted-average Exercise Price Outstanding beginning balance	$ 0.75	$ 0.75
Weighted-average Exercise Price, Granted	0.05	0.75
Weighted-average Exercise Price, Exercised	0	0
Weighted-average Exercise Price, Expired/Forfeited	0	0
Weighted-average Exercise Price Outstanding ending balance	0.05	$ 0.75
Weighted-average Exercise Price, Exercisable	$ 0.05
Remaining Contractual Term (years) Outstanding beginning balance	3 years 4 days	3 years 9 months 11 days
Remaining Contractual Term (years), Granted	9 years 10 months 25 days	4 years
Remaining Contractual Term (years) Outstanding ending balance	9 years 7 days	3 years 4 days
Remaining Contractual Term (years), Exercisable	9 years 7 days
Aggregate Intrinsic Value Outstanding beginning balance	$ 0	$ 0
Aggregate Intrinsic Value, Granted	0	0
Aggregate Intrinsic Value Outstanding ending balance	$ 0	$ 0

13. Warrants (Details Narrative

13. Warrants (Details Narrative) - USD ($)	Nov. 04, 2017	Mar. 08, 2017	Nov. 04, 2016	Oct. 31, 2017	Oct. 31, 2016	Feb. 28, 2017
Number of warrant shares issued				729,370	1,008,114
Expected term				4 years	4 years
Expected volatility					100.00%
Expected dividend rate				0.00%	0.00%
Fair value of warrants				$ 379,893
Amortization		$ 27,960		1,119,945
Exercise price of warrants		$ 0.02				$ 0.15
Proceeds from debt financing				$ 300,000	$ (300)
Warrants forfeited				77,150,000
Chief Operating Officer [Member]
Warrants forfeited				53,300,000
Issuance of common stock				7,500,000
Common stock received from exercise of warrants				4,675,439
Chief Technology Officer [Member]
Warrants forfeited				23,850,000
Issuance of common stock				7,500,000
Common stock received from exercise of warrants				2,092,105
March 8, 2017 [Member]
Risk free interest rate				2.57%
Expected term				10 years
Expected volatility				153.00%
Expected dividend rate				0.00%
Fair value of warrants				$ 1,119,945
Amortization				$ 1,119,945
Exercise price of warrants				$ 0.02
During January 2017 and February 2017 [Member]
Expected term				3 years
Expected volatility				106.00%
Expected dividend rate				0.00%
During January 2017 [Member]
Number of warrant shares issued				1,200,000
Fair value of warrants				$ 22,320
During February 2017 [Member]
Number of warrant shares issued				600,000
Fair value of warrants				$ 11,160
February 28, 2017 [Member]
Exercise price of warrants				$ 0.15
Minimum [Member]
Risk free interest rate				1.22%	1.50%
Expected volatility				97.00%
Minimum [Member] | During January 2017 and February 2017 [Member]
Risk free interest rate				1.43%
Maximum [Member]
Risk free interest rate				1.57%	1.74%
Expected volatility				100.00%
Maximum [Member] | During January 2017 and February 2017 [Member]
Risk free interest rate				1.50%
Human Amnion Product [Member]
Commercially available product percentage				25.00%
Third Product [Member]
Commercially available product percentage				15.00%
Fourth Product [Member]
Commercially available product percentage				10.00%
Ian T. Bothwell [Member]
Number of warrant shares issued				31,800,000
Risk free interest rate				1.79%
Expected term				10 years
Expected volatility				152.00%
Expected dividend rate				0.00%
Fair value of warrants				$ 1,879,380
Amortization				$ 1,722,765
Exercise price of warrants			$ 0.06	$ 0.06
Warrant vesting description				Immediately on the Effective Date, 50% of the Warrant shall vest and the remaining 50% shall vest in 18 equal monthly installments beginning on November 30, 2016
Consummation of equity percentage				225.00%
Proceeds from debt financing			$ 1,500,000	$ 1,500,000
Dr. Maria Ines Mitrani [Member]
Number of warrant shares issued				10,000,000
Risk free interest rate				1.79%
Expected term				10 years
Expected volatility				152.00%
Expected dividend rate				0.00%
Fair value of warrants				$ 591,000
Amortization				$ 591,000
Exercise price of warrants			$ 0.06	$ 0.06
Dr. Bruce Werber [Member]
Number of warrant shares issued				31,800,000
Risk free interest rate				1.79%
Expected term				10 years
Expected volatility				152.00%
Expected dividend rate				0.00%
Fair value of warrants				$ 1,879,380
Amortization				$ 1,879,380
Exercise price of warrants			0.06	$ 0.06
Executive Employment Agreement [Member] | Terrell Suddarth [Member]
Exercise price of warrants	$ 0.02		0.02
Executive Employment Agreement [Member] | Terrell Suddarth [Member] | Maximum [Member]
Number of warrant shares issued	23,850,000
Executive Employment Agreement [Member] | Terrell Suddarth [Member] | Third Available Product [Member]
Commercially available product percentage	15.00%
Executive Employment Agreement [Member] | Terrell Suddarth [Member] | Human Amnion Product [Member]
Commercially available product percentage	25.00%
Executive Employment Agreement [Member] | Terrell Suddarth [Member] | Fourth Available Product [Member]
Commercially available product percentage	10.00%
Executive Employment Agreement [Member] | Ian T. Bothwell [Member]
Exercise price of warrants	$ 0.06		0.06
Consummation of equity percentage	25.00%
Proceeds from debt financing	$ 1,500,000
Executive Employment Agreement [Member] | Ian T. Bothwell [Member] | Maximum [Member]
Number of warrant shares issued	31,800,000
Consummation of equity percentage	25.00%
Executive Employment Agreement [Member] | Dr. Maria Ines Mitrani [Member]
Exercise price of warrants	$ 0.06		0.06
Executive Employment Agreement [Member] | Dr. Maria Ines Mitrani [Member] | Maximum [Member]
Number of warrant shares issued	10,000,000
Executive Employment Agreement [Member] | Dr. Bruce Werber [Member]
Exercise price of warrants	$ 0.06		$ 0.06
Executive Employment Agreement [Member] | Dr. Bruce Werber [Member] | Maximum [Member]
Number of warrant shares issued	31,800,000
Securities Purchase Agreement [Member] | Ian T. Bothwell [Member]
Consummation of equity percentage				25.00%
Proceeds from debt financing	$ 300,000		$ 300,000	$ 300,000
Issuance of common stock				1,000,000
Employment Agreement [Member]
Exercise price of warrants		0.02
Employment Agreement [Member] | March 8, 2017 [Member]
Number of warrant shares issued				23,850,000
Risk free interest rate				2.57%
Expected term				10 years
Expected volatility				153.00%
Expected dividend rate				0.00%
Fair value of warrants				$ 469,845
Amortization				$ 469,845
Exercise price of warrants				$ 0.02
Warrant vesting description				Immediately on the Effective Date, 50% of the Warrant shall vest and, thereafter, the remaining 50% shall vest in 18 equal monthly installments beginning on March 31, 2017
Participation Agreement [Member]
Exercise price of warrants		$ 0.15
Participation Agreement [Member] | March 8, 2017 [Member]
Number of warrant shares issued				150,000
Risk free interest rate				1.38%
Expected term				3 years
Expected volatility				106.00%
Expected dividend rate				0.00%
Fair value of warrants				$ 4,770
Exercise price of warrants				$ 0.15
Participation Agreement [Member] | February 14, 2017 [Member]
Proceeds from debt financing				$ 150,000

14. Commitments and Contingen_3

14. Commitments and Contingencies (Details)	Oct. 31, 2017USD ($)
Ethan NY [Member]
2,016	$ 104,785
2,017	117,714
2,018	121,245
2,019	124,882
2,020	117,616
2,021	0
Total	586,242
Anu Life Sciences Inc [Member]
2,018	95,421
2,019	99,663
2,020	109,049
2,021	111,782
2,022	75,758
Total	$ 491,673

14. Commitments and Contingen_4

14. Commitments and Contingencies (Details Narrative)	Aug. 10, 2018USD ($)Days$ / shares	Nov. 04, 2017USD ($)$ / sharesshares	Mar. 08, 2017USD ($)$ / shares	Nov. 04, 2016USD ($)$ / shares	Oct. 01, 2016USD ($)	Aug. 01, 2015USD ($)shares	Jun. 20, 2018USD ($)Days	Oct. 31, 2017USD ($)ft²$ / sharesshares	Oct. 31, 2016USD ($)$ / sharesshares	Feb. 28, 2017$ / shares	Feb. 23, 2017USD ($)	Jun. 30, 2016USD ($)
Net monthly sales								$ 569,845	$ 184,881
Warrant to purchase shares of common stock | shares								729,370	1,008,114
Exercise price of warrants | $ / shares			$ 0.02							$ 0.15
Proceeds from debt financing								$ 300,000	$ (300)
Security deposit								$ 42,275	$ 5,000
Preferred stock, par value | $ / shares								$ 0.001	$ 0.001
Preferred stock, shares authorized | shares								10,000,000	10,000,000
Anu Life Sciences Inc [Member]
Minimum monthly lease payments								$ 491,673
March 8, 2017 [Member]
Exercise price of warrants | $ / shares								$ 0.02
Chief Executive Officer [Member]
Base salary									$ 91,845
Exercise price of warrants | $ / shares			0.001
Chief Executive Officer [Member] | March 8, 2017 [Member]
Warrant to purchase shares of common stock | shares								79
Exercise price of warrants | $ / shares								$ 0.001
Chief Financial Officer [Member]
Exercise price of warrants | $ / shares			0.001
Chief Financial Officer [Member] | March 8, 2017 [Member]
Warrant to purchase shares of common stock | shares								79
Exercise price of warrants | $ / shares								$ 0.001
Chief Science Officer [Member]
Exercise price of warrants | $ / shares			0.001
Chief Science Officer [Member] | March 8, 2017 [Member]
Warrant to purchase shares of common stock | shares								79
Exercise price of warrants | $ / shares								$ 0.001
Employment Agreement [Member]
Exercise price of warrants | $ / shares			$ 0.02
Employment Agreement [Member] | March 8, 2017 [Member]
Warrant to purchase shares of common stock | shares								23,850,000
Exercise price of warrants | $ / shares								$ 0.02
Five-Year Lease Agreement [Member] | Anu Life Sciences Inc [Member]
Security deposit								$ 37,275
Laboratory and administrative office space | ft²								3,500
Lease expiration date								Jun. 30, 2022
Conversion, description								(i) $0.15, and (ii) 60% of the lowest daily volume weighed average price in the 20 trading days prior to the conversion Date.
Initial carrying amount								$ 759,569
Securities Purchase Agreement [Member]
Initial carrying amount								333,333
Securities Purchase Agreement [Member] | October 31, 2017 [Member]
Original issue discount and accrued interest								$ 536,820
Two Employees [Member]
Stock issued during period, shares, restricted stock | shares						225,000
Two Employees [Member] | Employment Agreement One[Member] | Net Profit Margin Less Than 35% [Member]
Net monthly sales						$ 50,000
Net profit margin on aggregate sales, percentage						35.00%
Two Employees [Member] | Employment Agreement Two [Member] | Net Profit Margin Less Than 35% [Member]
Base salary						$ 6,000
Two Employees [Member] | Employment Agreement Two [Member] | Net Profit Margin Less Than 35% [Member] | Minimum [Member]
Net monthly sales						50,000
Two Employees [Member] | Employment Agreement Two [Member] | Net Profit Margin Less Than 35% [Member] | Maximum [Member]
Net monthly sales						$ 75,000
Net profit margin on aggregate sales, percentage						35.00%
Two Employees [Member] | Employment Agreement Three [Member] | Net Profit Margin Less Than 35% [Member]
Base salary						$ 9,000
Two Employees [Member] | Employment Agreement Three [Member] | Net Profit Margin Less Than 35% [Member] | Minimum [Member]
Net monthly sales						75,000
Two Employees [Member] | Employment Agreement Three [Member] | Net Profit Margin Less Than 35% [Member] | Maximum [Member]
Net monthly sales						$ 100,000
Net profit margin on aggregate sales, percentage						35.00%
Two Employees [Member] | Employment Agreement Four [Member] | Net Profit Margin Less Than 35% [Member]
Net monthly sales						$ 100,000
Net profit margin on aggregate sales, percentage						35.00%
Base salary						$ 15,000
A. Mitrani [Member] | Executive Employment Agreement [Member] | Chief Executive Officer [Member]
Base salary					$ 360,000
Accrued and unpaid signing bonus					100,000
Dr. Bruce Werber [Member]
Warrant to purchase shares of common stock | shares								31,800,000
Exercise price of warrants | $ / shares				$ 0.06				$ 0.06
Dr. Bruce Werber [Member] | Executive Employment Agreement [Member]
Exercise price of warrants | $ / shares		$ 0.06		0.06
Dr. Bruce Werber [Member] | Executive Employment Agreement [Member] | Chief Operating Officer [Member]
Base salary					360,000
Accrued and unpaid signing bonus					35,000
Dr. Bruce Werber [Member] | Executive Employment Agreement [Member] | Maximum [Member]
Warrant to purchase shares of common stock | shares		31,800,000
Ian T. Bothwell [Member]
Warrant to purchase shares of common stock | shares								31,800,000
Exercise price of warrants | $ / shares				$ 0.06				$ 0.06
Proceeds from debt financing				$ 1,500,000				$ 1,500,000
Ian T. Bothwell [Member] | Executive Employment Agreement [Member]
Exercise price of warrants | $ / shares		$ 0.06		$ 0.06
Proceeds from debt financing		$ 1,500,000
Ian T. Bothwell [Member] | Executive Employment Agreement [Member] | Chief Financial Officer [Member]
Base salary					360,000
Accrued and unpaid signing bonus					35,000
Ian T. Bothwell [Member] | Executive Employment Agreement [Member] | Maximum [Member]
Warrant to purchase shares of common stock | shares		31,800,000
Ian T. Bothwell [Member] | Securities Purchase Agreement [Member]
Proceeds from debt financing		$ 300,000		$ 300,000				300,000
Dr. Maria Ines Mitrani [Member]
Unpaid expenses, salary and consulting fees								$ 84,000
Warrant to purchase shares of common stock | shares								10,000,000
Exercise price of warrants | $ / shares				$ 0.06				$ 0.06
Dr. Maria Ines Mitrani [Member] | Executive Employment Agreement [Member]
Base salary			$ 300,000
Exercise price of warrants | $ / shares		$ 0.06		0.06
Dr. Maria Ines Mitrani [Member] | Executive Employment Agreement [Member] | Chief Science Officer [Member]
Base salary					250,000
Accrued and unpaid signing bonus					50,000
Dr. Maria Ines Mitrani [Member] | Executive Employment Agreement [Member] | Maximum [Member]
Warrant to purchase shares of common stock | shares		10,000,000
Terrell Suddarth [Member] | Executive Employment Agreement [Member]
Exercise price of warrants | $ / shares		$ 0.02		$ 0.02
Terrell Suddarth [Member] | Executive Employment Agreement [Member] | Chief Technology Officer [Member]
Base salary					300,000
Accrued and unpaid signing bonus					$ 35,000
Terrell Suddarth [Member] | Executive Employment Agreement [Member] | Maximum [Member]
Warrant to purchase shares of common stock | shares		23,850,000
Ethan NY [Member]
Security deposit								$ 18,585
Minimum monthly lease payments								586,242
Liabilities of discontinued operations								76,000
Estimated reserve for losses on lease								25,905
Impairment loss								$ 5,463
Ethan NY [Member] | Five-Year Lease Agreement [Member] | Eleven Months Ended June 30, 2016 [Member]
Minimum monthly lease payments									$ 104,785
Ethan NY [Member] | Five-Year Lease Agreement [Member] | Seven Months Ended June 30, 2016 [Member]
Minimum monthly lease payments												$ 66,500
Ethan NY [Member] | Five-Year Lease Agreement [Member] | December 2015 through October 2020 [Member]
Minimum monthly lease payments												$ 9,500
Ethan NY [Member] | Distribution Agreement [Member]
Source's non-payment outstanding											$ 4,815
Accredited Investors [Member]
Debt trading days | Days	30						30
Debt conversion price per share | $ / shares	$ 0.45
Debenture issued	$ 100,000						$ 150,000

15. Mint Organics (Details)

15. Mint Organics (Details)	12 Months Ended
	Oct. 31, 2017$ / sharesshares
Warrants, Total	237
Albert Mitrani [Member]
Warrants, Total	79
Exercise Price | $ / shares	$ 0.001
Ian T. Bothwell [Member]
Warrants, Total	79
Exercise Price | $ / shares	$ 0.001
Dr. Maria I. Mitrani [Member]
Warrants, Total	79
Exercise Price | $ / shares	$ 0.001

15. Mint Organics (Details Narr

15. Mint Organics (Details Narrative) - USD ($)	Nov. 04, 2017	May 17, 2017	Apr. 06, 2017	Mar. 29, 2017	Mar. 17, 2017	Mar. 08, 2017	Feb. 28, 2017	Feb. 15, 2017	Feb. 14, 2017	Nov. 04, 2016	Feb. 28, 2017	Jan. 31, 2017	Oct. 31, 2017	Oct. 31, 2016	Nov. 02, 2016
Proceeds from debt financing													$ 300,000	$ (300)
Common stock, shares authorized													750,000,000	750,000,000
Common stock, par value													$ 0.001	$ 0.001
Preferred stock, shares authorized													10,000,000	10,000,000
Preferred stock, par value													$ 0.001	$ 0.001
Number of preferred stock issued													0	0
Number of common stock warrants exercisable							150,000
Exercise price of warrants						$ 0.02	$ 0.15				$ 0.15
Fair value of warrant issued						34,949
Amortization						$ 27,960							$ 1,119,945
Number of common stock issued													111,464,987	104,214,982
Proceeds from sale of units											$ 30,000	$ 60,000	$ 400,000
Number of units sold during the period												100,000
Participation Agreement [Member]
Exercise price of warrants						$ 0.15
Employment Agreement [Member]
Exercise price of warrants						$ 0.02
Taddeo [Member] | Taddeo Agreement [Member]
Number of units sold during the period		1,000,000
Bothwell [Member] | Securities Purchase Agreement [Member]
Number of units sold during the period				1,000,000
Agents [Member] | Securities Purchase Agreement [Member]
Number of units sold during the period				2,000,000
Werber [Member] | Securities Purchase Agreement [Member]
Number of units sold during the period				1,000,000
Ian T. Bothwell [Member]
Proceeds from debt financing										$ 1,500,000			$ 1,500,000
Exercise price of warrants										$ 0.06			$ 0.06
Amortization													$ 1,722,765
Ian T. Bothwell [Member] | Securities Purchase Agreement [Member]
Proceeds from debt financing	$ 300,000									$ 300,000			$ 300,000
Ian T. Bothwell [Member] | Executive Employment Agreement [Member]
Proceeds from debt financing	$ 1,500,000
Exercise price of warrants	$ 0.06									$ 0.06
Related Party [Member]
Number of units sold during the period											250,000
Dr. Bruce Werber [Member]
Exercise price of warrants										0.06			$ 0.06
Amortization													$ 1,879,380
Dr. Bruce Werber [Member] | Executive Employment Agreement [Member]
Exercise price of warrants	0.06									0.06
Dr. Maria Ines Mitrani [Member]
Exercise price of warrants										0.06			$ 0.06
Amortization													$ 591,000
Dr. Maria Ines Mitrani [Member] | Executive Employment Agreement [Member]
Exercise price of warrants	0.06									0.06
Mint CEO [Member] | Taddeo Employment Agreement [Member]
Base salary													180,000
Adjustment of annual rate of base salary acquire of license													250,000
Health, dental and automobile expense per month													$ 1,000
Number of unregistered common stock shares granted													1,000,000
Mint CEO [Member] | Employment Agreement [Member]
Accrued and unpaid signing bonus													$ 25,000
Terrell Suddarth [Member] | Executive Employment Agreement [Member]
Exercise price of warrants	$ 0.02									$ 0.02
Common Stock [Member]
Number of units sold during the period											300,000	600,000	1,800,000
Class A Voting Common Stock [Member] | Participation Agreement [Member]
Common stock, shares authorized									550
Equity ownership percentage									100.00%
Series A Preferred Stock [Member]
Preferred stock, shares authorized													400	400
Preferred stock, par value													$ 0.001	$ 0.001
Number of preferred stock issued													400	400
Series B Preferred Stock [Member]
Preferred stock, shares authorized													1,000,000	1,000,000
Preferred stock, par value													$ 0.001	$ 0.001
Number of preferred stock issued													0	0
Series A Non-Convertible Preferred Stock [Member]
Preferred stock, shares authorized															10,000,000
Number of preferred stock issued															100
Series A Non-Convertible Preferred Stock [Member] | Chief Operating Officer [Member]
Number of preferred stock issued						100
Series A Non-Convertible Preferred Stock [Member] | Chief Science Officer [Member]
Number of preferred stock issued						100
Series A Non-Convertible Preferred Stock [Member] | CFO [Member]
Number of preferred stock issued						100
Series A Non-Convertible Preferred Stock [Member] | Chief Executive Officer [Member]
Preferred stock, par value															$ 0.001
Number of preferred stock issued															100
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized															10,000,000
Chief Operating Officer [Member]
Number of unregistered common stock shares granted				1,000,000
Number of units sold during the period											250,000
Chief Operating Officer [Member] | Series A Preferred Stock [Member]
Number of preferred stock issued						100
Chief Financial Officer [Member]
Exercise price of warrants						$ 0.001
Number of unregistered common stock shares granted				1,000,000
Chief Financial Officer [Member] | Series A Preferred Stock [Member]
Number of preferred stock issued						100
Investors [Member] | Participation Agreement [Member]
Non-controlling interest percentage									55.00%
Investments									$ 150,000
Proceeds from debt financing									$ 150,000
Chief Science Officer [Member]
Exercise price of warrants						$ 0.001
Chief Science Officer [Member] | Series A Preferred Stock [Member]
Number of preferred stock issued						100
Chief Executive Officer [Member]
Exercise price of warrants						$ 0.001
Base salary														$ 241,845
Chief Executive Officer [Member] | Series A Preferred Stock [Member]
Preferred stock, par value															$ 0.001
Number of preferred stock issued															100
Mr. Wayne Rohrbaugh [Member]
Number of preferred stock issued							150				150
Exercise price of warrants							$ 0.15				$ 0.15
Mr. Peter Taddeo [Member]
Number of preferred stock issued							150				150
Exercise price of warrants							$ 0.15				$ 0.15
Mint Organics Florida, Inc [Member]
Equity ownership percentage			3.00%
Proceeds from sale of units			$ 100,000
Number of units sold during the period			21.25
Mint Organics Florida, Inc [Member] | Consulting Agreement [Member]
Payments required to pay as monthly fee								$ 7,500
Number of common stock shares granted during the period								63.75
Mint Organics Florida, Inc [Member] | Class B Non-Voting Common Stock [Member]
Equity ownership percentage					10.00%
Conversion of stock, amount					$ 1,000,000
Conversion of stock, shares converted					212.5
Mint Organics Florida, Inc [Member] | Class B Non-Voting Common Stock [Member] | Participation Agreement [Member]
Common stock, shares authorized													10,000
Common stock, par value													$ 0.001
Common stock voting rights													The Class B Common Stock shall not be entitled to vote on any matters.
Mint Organics Florida, Inc [Member] | Class A Voting Common Stock [Member]
Common stock, par value							$ 0.001				$ 0.001
Number of common stock issued							2,125				2,125
Fair consideration for the initial issuance of common stock							$ 0.001				$ 0.001
Mint Organics Florida, Inc [Member] | Class A Voting Common Stock [Member] | Participation Agreement [Member]
Common stock, shares authorized													10,000
Common stock, par value													$ 0.001
Common stock voting rights													The Class A Common Stock shall have the sole right and power to vote on all matters on which a vote of shareholders is to be taken. In all matters, with respect to actions both by vote and by consent, each holder of shares of the Class A Common Stock shall be entitled to cast one vote in person or by proxy for each share of Class A Common Stock standing in such holder’s name on the transfer books of the Corporation.
Mint Organics Inc [Member] | Participation Agreement [Member]
Preferred stock, shares authorized									1,000
Preferred stock, par value									$ 0.001
Mint Organics Inc [Member] | Class B Non-Voting Common Stock [Member] | Participation Agreement [Member]
Common stock, shares authorized									1,000
Common stock, par value									$ 0.001
Mint Organics Inc [Member] | Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized							300				300
Preferred stock, par value							$ 0.001				$ 0.001
Preferred stock, stated value							$ 1,000				$ 1,000
Convertible preferred stock description							The amount of each share of the Series A Preferred Stock shall automatically convert into 1.5 shares of Class B Common Stock of Mint Organics upon the earlier of (a) the fifth anniversary of the date such share of Series A Preferred Stock was issued; or (b) Mint Organics’ receipt of the necessary licenses and permits required to operate business operations in the medical cannabis industry.
Percentage of outstanding capital stock represents the common stock conversion							45.00%
Mint Organics Inc [Member] | Class A Voting Common Stock [Member] | Participation Agreement [Member]
Common stock, shares authorized									1,000
Common stock, par value									$ 0.001
Mint Organics Inc [Member] | Investors [Member] | Series A Preferred Stock [Member]
Number of preferred stock issued							150				150
Mint Organics [Member]
Non-controlling equity holders percentage													45.00%
Accrued fees													$ 7,500
Non-controlling interests amount													$ 52,744
Mint Organics [Member] | Series A Preferred Stock [Member]
Preferred stock, shares authorized													300
Preferred stock, par value													$ 0.001
Percentage of outstanding capital stock represents the common stock conversion													45.00%

16. Discontinued Operations (De

16. Discontinued Operations (Details - Schedule of Assets and Liabilities) - USD ($)	Oct. 31, 2017	Oct. 31, 2016
Liabilities
Liabilities, total	$ 125,851	$ 125,851
Ethan NY [Member]
Assets
Cash	0	0
Inventories	0	0
Prepaid Expenses	0	0
Security Deposits	0	0
Property, Plant and Equipment, net	0	0
Assets, total	0	0
Liabilities
Accounts Payable	94,835	94,835
Accrued Expenses	31,016	31,016
Deferred Rent	0	0
Liabilities, total	$ 125,851	$ 125,851

16. Discontinued Operations (_2

16. Discontinued Operations (Details - Summary of Revenues and Expenses, Net and Net Income of Discontinued Operations) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Total Revenues	$ 0	$ 68,598
Total Expenses, net	0	265,753
Income (Loss) From Discontinued Operations	$ 0	$ 197,155

17. Segment Information (Detail

17. Segment Information (Details) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
Revenues	$ 569,845	$ 184,881
Gross profit	409,219	90,479
Net loss from continuing operations	(9,112,519)	(1,056,046)
Total assets	376,780	69,898
Patient Referral and Product Sales [Member]
Revenues	569,845	184,881
Gross profit	409,219	90,479
Net loss from continuing operations	(8,662,291)	(1,056,046)
Total assets	375,522	69,898
MMTC Activities [Member]
Revenues	0	0
Gross profit	0	0
Net loss from continuing operations	(309,841)	0
Total assets	$ 1,258	$ 0

17. Segment Information (Deta_2

17. Segment Information (Details Narrative)	12 Months Ended
	Oct. 31, 2017Integer
Segment Reporting [Abstract]
Number of operating segments	2